NZ623091B2

NZ623091B2 - Purine derivatives for the treatment of viral infections

Info

Publication number: NZ623091B2
Application number: NZ623091A
Authority: NZ
Inventors: Jean Francois Bonfanti; Frederic Marc Maurice Doublet; Werner EMBRECHTS; Jerome Michel Claude Fortin; Gowan David Craig Mc; Philippe Muller; Pierre Jean Marie Bernard Raboisson
Original assignee: Janssen Sciences Ireland Uc
Priority date: 2011-11-09
Filing date: 2012-11-08
Publication date: 2016-11-29

Abstract

Provided are adenine derivative compounds of the general formula (I), wherein the variables are as defined in the specification. The compounds are modulators of toll-like receptor 7 (TLR7). The compounds may be useful in the treatment of viral infections.

Description

/072090 PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS The current invention relates to purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral ions.

The present invention relates to the use of purine derivatives in the treatment of viral infections, immune or inflammatory disorders, y the modulation, or agonism, of toll-like-receptors (TLRs) is involved. Toll—Like Receptors are primary transmembrane ns characterized by an extracellular leucine rich domain and a cytoplasmic extension that contains a conserved region. The innate immune system can recognize pathogen-associated molecular ns via these TLRs expressed on the cell e of certain types of immune cells. Recognition of foreign pathogens activates the production of cytokines and upregulation of co-stimulatory molecules on phagocytes.

This leads to the modulation ofT cell behaviour.

It has been estimated that most mammalian species have between ten and fifteen types of Toll-like receptors. Thirteen TLRs (named TLR1 to TLR13) have been identiﬁed in humans and mice together, and equivalent forms of many of these have been found in other mammalian species. However, lents of certain TLR found in humans are not present in all mammals. For example, a gene coding for a protein analogous to TLR10 in humans is present in mice, but appears to have been damaged at some point in the past by a retrovirus. On the other hand, mice express TLRs 11, 12, and 13, none of which are represented in humans. Other mammals may express TLRs which are not found in . Other non-mammalian species may have TLRs distinct from mammals, as demonstrated by TLR14, which is found in the Takifugu pufferﬁsh. This may complicate the process of using experimental animals as models of human innate immunity.

For a review on toll—like receptors see for instance the following journal article: Hoffmann, J.A., Nature, 426, p33-38, 2003.

Compounds ting activity on Toll—Like receptors have been previously described such as purine derivatives in , e derivatives in WO 98/01448 and WO 99128321, and pyrimidines in .

However, there exists a strong need for novel ike receptor modulators having preferred selectivity, higher potency, higher metabolic stability, higher solubility and an improved safety profile ed to the compounds of the prior art.

In accordance with the present invention compounds of formula (l) are provided or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein Y is (C14)alkylene, R1 is a heteroaryl1 and R2 an aryl2 or a cyclyl.

The term heteroaryl1 means imidazolyl, pyridyl, pyrimidyl, pyrrolyl, pyrazolyl, furyl, oxazolyl, oxadiazolyl, isoxazolyl, nyl or thiazolyl. Heteroaryl1 is optionally substituted by one or more substituents independently selected from hydroxyl, C1- 5 alkyl, C14 alkoxy, trifluoromethyl, C3.5 cycloalkyl, phenyl, halogen, yl-CM alkyl, C14—alkoxy- CM-alkyk or C1-4alkyl-diethoxyphosphoryl.

The term aryl2 includes , naphtyl, anthracenyl and phenanthrenyl and is preferably phenyl. Aryl2 is ally substituted by one or more substituents independently selected from hydroxyl, 01-6 alkyl, 01-4 alkoxy, trifluoromethyl, COzRa, R4R5N—C14—alkyln n, hydroxy|~ CM atkyl-, NR5R7, C(O)R6 , C(O)NR6R7, C1- 4alkyl-diethoxyphosphoryl or Cmalkyl-phosphonic acid.

R3 is selected from H and 01-6 alkyl.

R4 and R5 taken together with the nitrogen, to which they are both attached, form a heterocycle selected from the group consisting of: WO 68438 “N D “N ‘N x '3 K/N F \ R5 and R7 are each independently selected from H, C1.s-aikyi or CMalkoxy.

The term “heterocyclyl” refers to tetrahydropyran and heteroarylz.

The term heteroaryi2 includes pyridyl, tetrahydroisoquinoiinyl, imidazopyridinyl, quinolinyl, isoquinolinyl, pyrazinyi, pyrimidyl, naphtyridinyl, pyridazinyl, benzimidazolyl, benzothiazolyl, pyrazolyi, thiazoiyi, imidazoiyl, indazoiyl. Heteroaryi2 is optionally substituted by one or more tuents independently selected from halogen, hydroxyl, C1.5alky| ,C1.4alkoxy, oxy—CMalkyiamine or pyrrolidinyI—methanone.

In a further embodiment the current ion encompasses a compound of formula (i) n R1 is selected from the group comprising an imidazolyl, a pyrazolyl or a pyridinyl each of which is optionally substituted by one or more substituents independently selected from halogen, yi, 01.5 alkyl, C14 alkoxy or 03-5 cycioalkyl.

Preferred compounds ing to the ion are compounds listed in Table 1 and Table 2 respectively under the heading of the following numbers: 1, 4, 9, 28, 24, 25, 26, 35, 36, 48, 49, 50, 51 and 54.

Furthermore to the invention s a pharmaceutical composition comprising a compound of formula (i) or a pharmaceutically acceptable salt, solvate or rph thereof together with one or more pharmaceutically acceptable excipients, ts or carriers.

Part of the invention is also a compound of formuia (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition above mentioned for use as a medicament.

The invention also related to a compound of formula (1) or a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical composition above mentioned for use in the treatment of a disorder in which the modulation of TLR7 is involved.

The term “alkyl” refers to a straight-chain or branched-chain saturated aliphatic arbon containing the specified number of carbon atoms.

The term "halogen” refers to fluorine, ne, bromine or iodine.

The term “cycloalkyl” refers to a yclic ring containing the specified number of carbon atoms.

The term “alkoxy” refers to an alkyl (carbon and hydrogen chain) group ar bonded to oxygen like for instance a methoxy group or ethoxy group.

Pharmaceutically acceptable salts of the compounds of formula (l) include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Suitable base salts are formed from bases which form non- toxic salts.

The compounds of the invention may also exist in unsolvated and solvated forms. The term “solvate” is used herein to describe a molecular complex comprising the compound of the invention and one or more ceutically acceptable solvent molecules, for example, ethanol.

The term “polymorph” refers to the ability of the compound of the invention to exist in more than one form or crystal ure.

The compounds of the ion can be present in a so-called “tautomer(s)” formation refering to isomers of c compounds that readily interconvert by a chemical reaction called tautomerization. This on results in the formal migration of a hydrogen atom or proton, accompanied by a switch of a single bond and nt double bond.

The compounds of the present invention may be administered as crystalline or amorphous products. They may be obtained for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the ion or in combination with one or more other drugs. Generally, they will be administered as a formulation in ation with one or more pharmaceutically acceptable excipients. The term “excipient” is used herein to describe any ingredient other than the compound(s) of the invention. The choice of ent depends largely on factors such as the ular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the ceutical compositions of this invention, an effective amount of the particular compound, optionally in on salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically able carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form le, for example, for oral, rectal, or percutaneous administration. For example, in preparing the compositions in oral dosage form, any of the usual ceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, s and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations that can be converted, shortly before use, to liquid forms. In the compositions suitable for aneous stration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the d compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot—on, as an ointment. The nds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be stered to the lungs in the form of a on, a sion or a dry powder.

It is especially advantageous to formulate the entioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage.

Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to e the desired therapeutic effect in association with the required W0 2013[068438 pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated s), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

Those of skill in the treatment of infectious diseases will be able to determine the effective amount from the test results presented after. in l it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to ster the ed dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.

The exact dosage and frequency of administration depends on the particular compound of formula (l) used, the particular condition being treated, the severity of the condition being d, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount may be lowered or sed depending on the response of the treated subject and/or ing on the evaluation of the physician prescribing the compounds of the instant invention. The effective amount ranges mentioned above are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.

Ex erimental Section: overall scheme in the re aration offinal com ounds Method1 .

NCINHZ NC NVOV I _______ § | __________ 1 ---------- e IN)N NBS, THF NC NHz C_H(OEt)3 NC NH2 benzylamlne H2N dloxane N\ NH2 HZN """""" "’ Cl l \>--Br ------------ -> Ci \ \O N/ I N\>—O CC'3CN N N CH3ONa /O\()%N N \ 082003 Ci CH3OH NH2 NH2 / N N N N/ ------------ , | \>—OH -—--——-——----* [ \>—OH ,O \ N 1. 6N HCl H N N O H’0 \N 2. LiOH, THF, water 0 NH2 0 ng agent NH2 NH2 0 N/ N N/ N m 5E \>—0H l \>—OH N N N ______________ ., R1 -_____________,, R1 Nﬁ/kN R2 0 \ NH4Ac NH toluene I > | NC NH2 dioxane NC NH2 Preparation of Intermediate A-1.

Diaminomaleononitrile (6 g, 55 mmol) and triethylorthoformate (9.2 mL, 55 mmol) were combined in oxane (95 mL) and heated under distillation conditions until 65 mL of 1,4-dioxane/ethanol had been ted. The on mixture was cooled to room temperature and the solvent evaporated in vacuo. The residue was puriﬁed by column tography using a petroleum ether to 25% ethyl acetate in petroleum ether gradient to give 5 g of A-1.

NCINVOV benzylamine It? NC NH2 KG A-1 3-1 Preparation of intermediate B-1.

Benzylamine (2.86 mL, 26.3 mmol) was added dropwise to a solution of A-1 (4.1 g, mmol) and aniline hydrochloride (50 mg) in ethanol (80 mL), stirring at 10°C. The reaction mixture stirred at room temperature for 18 hours. The reaction mixture was added dropwise to 1M NaOH (50 mL), stirring at 10°C, and the resultant suspension stirred at room temperature for 18 hours. The solid was collected by filtration, washed with water and dried in vacuo. The title compound was obtained as off white solid, B-1 (4 9)- NC NC N N I\> NBS, THF I \>'Br N ——> N B-1 C-1 Preparation of intermediate C-1. osuccinimide (4 g, 22 mmol) was added nwise to a suspension of 8-1 (4 g, 20 mmol) in THF (50 mL) and the on mixture stirred at room temperature for s. The solvent was evaporated in vacuo and the residue extracted from a saturated aqueous solution of NaHCOs (50 mL) with ethyl acetate (300 mL), dried over Na2804, the solids were removed by filtration, and the solvents of the filtrate were removed under reduced re. The residue was puriﬁed via column chromatography using a dichloromethane to 5% methanol in dichloromethane gradient. The best fractions were pooled, the solvents were removed under reduced pressure to afford a pink solid, C-1 (3 g). jEN\>—_BrN CI>LClNCN N/ —___.__>CI CI\‘/k HZN \\© CSQCOg N\>\:©Br c-1 0-1 Preparation of intermediate D-1.

Trichloroacetonitrile (4.8 g, 17.3 mmol) was added to a suspension of C-1 (4 g, 14.4 mmol) and 032003 (9.4 g, 29 mmol) in toluene (50 mL) and the reaction e was stirred at room temperature for 48 hours. The mixture was poured into water (1 00 mL) and extracted with ethyi e (3 x 50 mL), dried over Na2804, the solids were removed by filtration, and the ﬁltrate was concentrated in vacuo. The residue was suspended in l (20 mL) and stirred at room temperature for2 hours. The resultant solid was ted by ﬁltration and washed with methanol to yield an off white solid, D-‘l (2.7 g). :hjaiN\ N / MeONa, MeOH 2 _OO NZCQ___, kg Nzﬂ D-1 E-1 F-1 Preparation of intermediate F-1 Sodium methoxide (2.4 g, 0.06 mol) was added to a suspension of D-1 (5 g, 12 mmol) in methanol (100 mL) and the reaction mixture was heated at reflux for 16 hours. The mixture was cooled in an ice—water bath and quenched with water. The methanol was evaporated in vacuo and the residue was extracted with ethyl acetate. The organic layer was dried and trated to afford F-‘l (4.6 g, crude).

F-1 (3.1 W0 2013;068:138 -1 0- Preparation of Intermediate G-1. ediate F-1 (4.6 g, 15 mmol) was suspended in 6N HCl(aq.)(75 mL) and the reaction mixture was stirred for 32 hours at room temperature. The e was neutralized with ammonia and the resultant itate was collected by ﬁltration and washed with water to afford 6-1 (3.2 g).

NH2 H I >=O HO \ /O \ —-————-> N N N N 2N NaOH 0 MeOH G-1 \\© Preparation of ediate H-1. 2N NaOH (aq.) was added to a solution of G-1 (1 g, 3.34 mmol) in methanol (50 mL) and the reaction mixture was stirred at room temperature for 2 hours. Methanol was removed under reduced pressure and the reaction mixture was acidiﬁed to pH 2 with 2N HCl (aq). The resultant precipitate was collected by filtration and washed with water to afford H-1 (0.95 g).

NH2 NH2 H H HO N O N / N / Kl! l >=O EDCHCI, pyridine O MW, 40min, 110°C KG Preparation of ediate M.

A mixture of H-1 (500 mg, 1.4 mmol), Aminoketone 2 (284 mg, 1.6 mmol) and EDCI (460 mg, 2.4 mmol) in pyridine (10 mL) was heated in the microwave to 110 degrees C for 0.5 hour. The mixture was concentrated to give the crude product which was washed with acetonitrile (10 mL) and cold water to give the intermediate product M, as an off-white solid (0.5 g). -1 1- Compound 1.

NH4OA'c (59) was added to a vial and heated in an oil bath until melted. Then M (100 mg) was added and the reaction mixture was heated in the microwave for 1 hour at 180°C. The mixture was poured into water and extracted with a mixed organic solvent (dichloromethane: isopropanoi 3:1, 2 x 60 mL), dried and concentrated. The crude product was purified by preparative HPLC to afford a yellow solid, 1 (105 mg). nd 2.

Compound 2 was synthesized according to the procedure to synthesize compound 1 (230 mg). nd 3. nd 3 was synthesized according to the procedure to synthesize compound 1 (205 mg). -1 2- General rocedure for the re aration of aminoketones.

General Chemical Scheme: 0 SOC'Z O CHaNz O HCl/dioxane 0 R4 ———————— 9 R—<— --------- i- R—( ————————> R—<_ OH toluene, reﬂux Cl 320, 0°C —_NE Cl A ylic acid (1) is converted to the corresponding acid chloride 2 via thionyl chloride. It is also possible to employ other nating , for example oxalyl chloride or phosphorous oxychloride). The acid chloride (2) is treated with diazomethane at lower temperature to afford a diazoketone (3). Diazoketone (3) is converted to its alfa-chloroketone (4) via addition of hydrochloric acid at low temperature. The chlorine of the hloroketone (4) is displaced by an azide, from an appropriate azide source like sodium azide, in the presence of, usually, a dipolar ' aprotic solvent, for example DMSO.

Preparation of aminoketone 1.

Reaction scheme: 0 30012 O CH3N2 0 0—(0H HCI/dioxane O —> ———> ———"~" toluene. reﬂux Cl EtzO, 0°C "NEN THF, 0°C m A B c D NaNa 0 H2. F’d/C —> ﬂ omso, RT N3 MeOH NH2 .HCI E F Step 1. To a solution of A (15 g, 0.13 mol) in toluene (50 mL) was added 80012 (15 mL). The reaction e was refluxed for 3h. Toluene was removed under reduced pressure. The acid chloride product was obtained as a brown liquid (16 g) and used in the next step directly.

Step 2. To a solution of B (16 g, 0.12 mol) in diethylether (100 mL) was added CH2N2 (200 mL) at 0°C. The reaction mixture was stirred for 2 h at this temperature. The ether was d in vacuo at room temperature. The product was puriﬁed by flash tography (silica gel, eluent: petroleum ether: ethyl acetate 10:1) to give C (12 g). 1H NMR (CDCl3,400MHz): 5 (ppm) 5.18 (br. 3., 1H), 2.85 (br. s., 1H), 1.45 — 1.81 (m, 8H)).

Step 3. To a solution of C(12 g, 0.096 mol) in THF (65 mL) was added 4N HCI/dioxane dropwise at 0°C. The reaction was monitored by TLC. The reaction was neutralized with NaH003(sat. aq.). The mixture was extracted with ethyl acetate (2 X 150mL), dried and concentrated to give D (11 g). This product was used to next step ately. 1H NMR ,4OOMH2): 5 (ppm) 4.10 (s, 2H), 3.04 (quin, J=7.3Hz, 1H), 1.54 - 1.87 (m, 8H) Step 4. To a solution of D (7.3 g, 0.05 mol) in DMSO (30 mL) was added NaNs (3.9 g, 0.06 mol). The reaction was stirred for overnight and monitored by TLC. The reaction was poured into water (50 mL) and extracted with ethyl acetate (2 x 100mL), dried over sodium e, the solids were removed by ﬁltration and the solvents of the filtrate were removed under reduced pressure. The crude t was purified by silica gel chromatography using a petroleum ether to ethyl acetate nt to afford E (5.28 g). 1H NMR (CDCl3,4OOMHz): 5 (ppm) 3.93 (s, 2H), 2.83 (quin, J=7.3 Hz, 1H), 1.56 - 1.84 (m, 8H) Step 5. A mixture of E (3.28 g, 0.02m0l), conc. HCl (1.8 mL, 0.02 mol) and 19 Pd/C (10%) in 30 mL of methanol was stirred for overnight under 50psi of hydrogen atmosphere. The reaction mixture was ﬁltered and concentrated to give Aminoketone-1 (2 g). 1H NMR (MeOD ,400MHz): 5 (ppm) 4.03 (s, 2H), 3.01 - 3.12 (quin, J=7.3 Hz, 1H), 1.67 - 1.98 (m, 8H) WO 68438 Aminoketone-2 i—NHZ ,HCI Aminoketone 2 Aminoketone-2 was prepared according to the procedure to prepare Aminoketone—t.

Aminoketone 3 NH2 ,HCl Aminoketone 3 Aminoketone-3 was prepared according to the procedure to prepare etone—i. l Scheme in the re aration of final s Method 2 R: H2“ KMN\ N O// “2'” :N n \ \ 0 N/ \ Y N\ N HCl.dioxane N/ R2 \ R N NF \ vrBr ‘~ NO --------* NN N N— EtONa,EtOH N_ 43 HzN R1/S\/N\R3 R1/S\/N\R3 R2 R2 Preparation of compound 4: H2N H EV/N / N Nﬁéo N \ N H \ W?Br N ____, Mfr“ LG \@NH3 7N m MeOH H2N gNH C—1 4 A mixture of C-1 (1.6 g, 5.78 mmol) (its synthesis as such is described in W020060117670 on pages 59-60: “Preparation 6, 7 and 8” respectively to obtain AminobenzyIbromo—1H-imidazoIecarbonitrile) and 2—cyano—imidazole (592 mg,6.35 mmol) in NH3/MeOH (7N) (60 mL) were stirred at 140°C for 48 hours in a pressure vessel reactor. The solvent was evaporated. The crude compound was ed by column chromatography over silica gel column (15-40um,409), in DCM/MeOH/NH4OH 97/3/05 —> 95/5/05) to give compound 4 (78 mg, 4.4% yield).

Alternative 3 nthesis of com ound 1: \Si’/ ;N HzN H 1' V’EP/ N N J4 N/ \ \Fo N\ N N \ \YB‘ EtONa/EtOH ~N N N._ HZN \’© 2- HCI (37% in H20) NaF,THF/MeOH V§/NH C—1 1 EtONa (904 mg; 13.3 mmol) was added to a solution of o-imidazole M (0.7 g; 2.66 mmol) and ediate C-1 (736 mg; 2.66 mmol) in EtOH (30 mL). The e was stirred at 90°C for 16 h. The solvent was removed under reduced pressure. The crude was purified by preparative LC (irregular SiOH 459 Merck, mobile phase 97/3/01 to 95/5/05) to give 0.51 g of the SEM—protected ethoxy intermediate as a lightly yellow solid (38% yield).

HPLC Rt (min) = 7.45 ; MS M+ (H*): 506 method (v2003v2002) Step 2: NaF (170 mg; 4.05 mmol) was added to a solution of SEM-protected ethoxy intermediate (0.41 g; 0.811 mmol) in THF (28 mL), HCl (37% in H20) (28 mL) and MeOH (10 mL). The mixture was stirred at 40°C for 16h. The mixture was cooled to RT and a 10% solution of K2003 was added until the pH of the solution was basic. The aqueous layer was saturated with K2003 powder and the product was extracted with DCM/MeOH (5%) (3 times). The combined organic layers were dried over M9804, ed and the solvent was removed under reduced pressure. The crude was ed by preparative LC (irregular SiOH 15-40um, mobile phase DCM/MeOH/NHaaq 95/5/05 to 90/10/0.5) to give 120 mg of compound 1 as a white powder (43% yield).

WO 2013068438 -1 5- S nthesis of the 2-c ano-imidazole intermediates: Synthesis of intermediate J-1: /Si’ 'c' \Si/VOVCI <:::> 3 N‘ NH37NinmeOH 5_/ \N‘> ———+ r0 —""“‘——> + N g [>‘J/ NaCN,EtOH ﬂ NaH/THF & /> J-1a J..1b /Sl'/ BrCN /// DMAP,DMF N NaCN (360 mg; 7.35 mmol) was added to a suspension of cyclopropane- carboxaidehyde (5 g; 71.3 mmol) and ethyl-isocyanide (13.7 g; 69.9 mmol) in EtOH (200 mL). The resulting mixture was stirred for 1 h at RT. The solvent was d under reduced pressure and the residue was washed with a mixture of heptane/ether (1:1). The beige dried powder was stirred in NH3/MGOH 7N (480 mL; 3.36 mol) and the e was stirred at 100°C in steel bomb for 16 h. The mixture was cooled to RT and the solvent was ated under reduced pressure. iPrZO was added to the residue and the solid was ﬁltered. The te was evaporated to dryness and the crude was puriﬁed by preparative LC on (Irregular SiOH 20-450m 10009 DAVISIL). Mobile phase (0.5% NH4OH, 94% DCM, 6% MeOH). The pure fraction was collected and evaporated to give 4.9 g of intermediate J-1a as a brown oil (65% yield). 1H NMR (DMSO-de, 400MHz) : 5 (ppm) 8.60 (br. s., 1H), 7.58 (s, 1H), 6.76 (s, 1H), 1.85 (m, 1H), 0.86 (m, 2H), 0.71 (m, 2H).

J-1a (4.84 g; 44.8 mmol) in THF (60 mL) was added dropwise to a suspension of NaH (1.97 g; 49.2 mmol) in THF (200 mL) at 0°C under N2. The mixture was stirred at RT for 30 min and SEM-Cl (9.9 mL; 55.9 mmol) in THF(20 mL) was added dropwise at 0°C. The mixture was stirred at RT under N2 for 16 h. Water was added and the product was extracted with DCM. The organic layer was dried over M9804, filtered and concentrated under reduced pressure. The crude was purified by ative LC (Irregular SiOH 20-45 pm, 150g Merck, Mobile phase Gradient from 50% DCM, 50% heptane to 100% DCM). The ons containing pure compound were combined and the solvent was removed under reduced pressure to give 6.6 g of J-1b as a yellow oil (62%).

Mixture of 2 regioisomers : 70/30 Minoritory regioisomer : 1H NMR (DMSO—de, 400MHz): 5(ppm) 7.84 (s, 1H), 8.58 (s, 1H), 5.34 (s, 1H), 3.45 (t, J = 8.08 Hz, 2H), 1.73—1.78 (m, 1H), 0.80-0.88 (m, 2H). 0.72-0.74 (m, 2H), 0.52-0.57 (m, 2H), -0.04 (s, 9H).

Majoritory regioisomer : 1H NMR (DMSO-de, 400MHz) : 5(ppm) 7.58 (s, 1H), 6.94 (s, 1H), 5.20 (s, 1H), 3.43 (t, J = 8.08 Hz, 2H), 1.73-1.78 (m, 1H), 0.80-0.88 (m, 2H), 0.72-0.74 (m, 2H), .82 (m, 2H), —0.04 (s, 9H).

BrCN (6.11 g; 57.7 mmol) was added to a solution of DMAP (7.05 g; 57.7 mmol) in DMF (60 mL) at 10°C. The reaction was exothermic to 35°C and a pale yellow precipitate was formed. The mixture was cooled to 10°C and J-1 b (5.5 g; 23.1 mmol) was added. The mixture was stirred at 40°C for 6 h. Water was added and product was extracted with EtZO (2 times). The combined organic layers were washed with brine, dried over M9804, ed and the solvent was d under d pressure.

The crude was puriﬁed by preparative LC (irregular SiOH 15—40 pm 220 g grace, mobile phase Heptane/DCM 50/50 to 10/90) to give 2.2 g impure J-1, which was further purified by preparative LC (irregular SiOH 15—40 pm 90 g Merck, mobile phase heptane/DCM 30/70) to give 0.94 g of J-1 as a e of two region—isomers(15% yield).

HPLC Rt (min) = 6.11 ;MS M+ (W): 284 (method v1004v1012) ative synthesis of intermediate J-1: /Si/ [/0 1- BuLi (1.6M in hexane) DMF/THF I’O TFAA [’0 —————-—-————-—> N N-~OH N ——> 2- NH20H VENV/ / DOM/Pyridine VEN K-‘i BuLi (1.6M in hexane)(11 mL; 17.6 mmol) was added to a solution of J-1b (3.5 g; 14.7 mmol) in THF (60 mL) at -50°C. The mixture was stirred at the same ature for 30 min and DMF (1.7 mL; 22 mmol) was added. The mixture was warmed slowly to RT in 1h and NH20H,HCI (970 mg; 29.4 mmol) was added and the mixture was stirred at RT for 16h. Water was added and the product was extracted with DCM (3 times), washed with brine, dried over M9804 and the solvent was d under reduced pressure to give 4.1 g (quantitative yield) of the mixture of isomers K-1 as yellow oil.

HPLC Rt (min) = 5.30, 5.41 and 5.90 ; Ms M+ (W): 282 (method v2002v2002) K-1 (3.1 g; 11 mmol) was ved in DCM (18 mL) and pyridine (19 mL) at RT. The mixture was cooled to 0°C and TFAA (4.6 mL; 33 mmol) was added. The mixture was stirred at RT for 24h. The solvent was removed under reduced pressure and the residue was dissolved in AcOEt. The organic layer was washed with water and brine, dried over M9804, filtered and the solvent was removed under reduced pressure. The crude was purified by preparative LC (irregular SiOH m QOg merck, mobile phase Heptane/DCM 30/70 to DCM 100%) to give 2.14 g of intermediate J-1 (73%) as a mixture of two isomers.

HPLC Rt (min) = 6.51 ; MS M+ (H+): 264 (method V2002V2002) l Scheme in the re aration of final roducts: Method 3 N\ NaCN/DMSO N\ N/ 1- MeONa/MeOH N / N , —> —------> :\> C, N N // N N Feel3 2- NH4CI NH 2 o HZN I N Br O O N/ \ | \>—O/ Ri/lkr N/ \Y HCl,dioxane NY R2 N N:N\ N N”— N NH k0 base R1/S\/NH RISE—NW3 -1 9- S nthesis of intermediate N-1.

N H2 NH2 N MSO N/ N Cl/’\\N l \> ———-——» N \NtrN> w N// w In a CEM microwave oven, 3 mixture of M-1 (its synthesis as such is described in W02006117670 pages 57~58 “Preparation 1-4" respectively to obtain 6-Amino benzyI-Z—chloro-7,9—dihydro-purin—8-one) (9.7 9, 37.351 mmoi), NaCN (3.11 g, 63.50 mmol) in DMSO (100 mL) was stirred at 150°C for 4h. The mixture was poured into water and the precipitate was filtered off, washed with water and dried under vacuum at 60°C to give 8.6 g of intermediate N-1.

HPLC Rt (min) = 5.23; MS M+ (H): 251 (method v2003v2002) Synthesis of intermediate 0-1.

FeCi3 (tip spatula) was added to a mixture of N-1 (3.70 9, 147.84 mmol) and NBS (26.2 9,147.845 mmol) in CH013 (60 mL). The mixture was stirred and ed for 3h and then cooled to RT.The itate was filtered off. The filtrate was evaporated and purified by ﬂash chromatography over silica gel um, 1209, CH2Cl2/CH30H 99—1) to give 4.59 of impure intermediate 0-1. The fraction was taken up CHgCiz and the precipitate was ﬁltered off to give 1.8 g of intermediate 0-1.

HPLC Rt (min) = 5.77 ; MS M+ (HCH30N+)I 370-372 (method V2003V2002) S nthesis of intermediate P-1.

//\Nlit:N/ \>—Br 1 MeONa/MeOH N/’ H2N \ ©2de N 01 R1 A mixture of 0-1 (0.82 g, 2.491 mmol), MeONa/MeOH (30wt% solution) (1.15 mL, 6.228 mmol) in MeOH (15 mL) was stirred at 50°C for 2h. NH4Cl (333 mg, 6.228 mmol) was added and the mixture was stirred and refluxed for 2h. The solvent was evaporated under reduced pressure. The crude was purified by flash chromatography over silica gel um, 909, /CH30H/NH4OH: 85—14—1 ). The pure fractions were collected and concentrated under reduced pressure to give 0.55 g of intermediate P-1 (74% yield).

HPLC Rt (min) = 4.46 ; MS M+ (H”): 298 (method V2003V2002) S nthesis of intermediate Q-1.

W HZN / Br N\ O N/ N/ \ R/ DBU EKDH “N ::> R1 V/S\/NHQ1N 2-bromocyclopropyl-propan-1~one (104 mg, 0.589 mmol) was added dropwise to a mixture of P4 (175 mg, 0.589 mmol) and DBU (0.264 mL, 1.766 mmol) in EtOH (5 mL). The mixture was stirred and refluxed for 5h. The solvent was concentrated under d re. The crude was purified by flash chromatography over silica gel (15-40um, 409, CH2Cl2/CH30H/NH4OH: 95/5/01). The pure fractions were collected and concentrated under reduced pressure to give 40 mg of intermediate Q-1. The crude compound was used directly in the next step.

HPLC Rt (min) = 5.35; MS M+ (W): 376 (method V1005V1012) S nthesis of final Com ound 5: HZN / HZN Néiw/N ]N1 \ / HCl 6N/dioxane N97; /o N:(L N ——> N \ \ N N:2\N \’© WNH Q-1 ”NH 5 A mixture of (1—1 (40 mg, 0.107 mmol) in HCl 6N (1 mL) and dioxane (1 mL) was d at RT for 6h. The mixture was half-evaporated under reduce pressure. The solution was cooled to 0°C, basiﬁed with NaHCOs and extracted with EtOAc—CH30H (90—10). The combined organic layers were dried over M9804, filtered and the solvent was evaporated under reduce pressure. The crude was puriﬁed by flash chromatography over silica gel (15-40pm, 109, CH2Cl2/CH30H/NH4OH:880.5) The pure ons were collected and concentrated under reduced pressure. The resulting solid (35 mg) was crystallized from EtZO to afford 25 mg of Compound 5 (64% yield, MP > 260°C).

Overall scheme in the re n of final roducts: Method 4 N \ NHz N \ NVOH \ aniline,HCl / ____>N\\ N + I ——-—> \SE—(_\>———T—H——> \ \>—Cl / N H2 / EtOH N / N HZN / \ 0 // > H2N IN/ / :N N\ NyO/ \ 5740 N- \\: HCl (37% in water) QN —>N$51_ \__</:\§___N EtONa/EtOH NaF,MeOH \ NH S\i\ Synthesis of intermediate T—1: ———-—>Xh§>N\anilineHCI N EtOH HZN R—1 8-1 T—1 S-1 (synthesis described in J. Med. Chem. 1996, 39, 13, 2586—2593) (1.14 g; 9.33 mmol) was added drop wise to a solution of R-1 (synthesis described in W02006/117670 ) (1.46 g; 8.89 mmol) and aniline,HCl (18 mg; 0.14 mmol) in EtOH (30 mL) at 10°C. The reaction mixture was stirred at RT for 20 h. An s solution of NaOH 3M (30 mL) was added dropwise to the solution at 10°C and the resultant mixture was stirred at RT for 1 h. The aqueous layer was extracted with DCM (3 times). The combined organic layers were washed with a saturated s solution of Ncho:;, dried over M9804, d and concentrated in vacuo to give 1.20 g of T-1 as a brown solid (63% yield). T-1 was used in the next step without further puriﬁcation.

HPLC Rt (min) = 4.45 ; MS M+ (H“): 214 (method V1010V1012) §ynthesis of intermediate U-1: \KNN N\\ \> NCS ) N\ HZN / \ N>—C| HZN / \ U-‘i A solution of NOS (475 mg; 3.56 mmol) in THF (10 mL) was added se to a on of T-1 (690 mg; 3.24 mmol) in THF (35 mL). The solution was stirred at RT for 20h under N2 flow. A solution of NCS (260 mg; 1.94 mmol) in THF (5 mL) was added drop wise to the solution. The solution was stirred at RT for 16h under N2 flow. The mixture was taken up with DCM, washed with a saturated aqueous solution of NaHCog, washed with brine, dried over Mg804, filtered and evaporated in vacuo to give 950 mg of a brown solid. The crude was purified by preparative LC (irregular SiOH 15-40 pm, 409 Grace, liquide sample, mobile phase: 98% DCM, 2% MeOH to 90% DCM, 10% MeOH).The fractions containing pure nd were combined and the t was removed in vacuum to give 200 mg of U-1 as a brown solid (25% yield).

HPLC Rt (min) = 5.13 ; MS M+ (H+): 248-250 (method v2012v2002) Synthesis of intermediate W-1: EtONa (398 mg; 5.85 mmol) was added to a solution of U-1 (290 mg ; 1.17 mmol) and V-1 (270 mg; 1.21 mmol) in EtOH (15 mL). The mixture was stirred at 90°C for 16 h.

The solvent was d under reduced pressure. The crude was ed by ative LC (irregular SiOH 15-40um, 509 Merck, solid sample, mobile phase 97/3/01). The fraction containing pure compound were combined and the solvent was removed to give 210 mg of W-1 as a lightly yellow solid (37% yield).

HPLC Rt (min) = 6.68; MS M+ (H+): 248—250 (method V101OV1012) S nthesis of Com ound 9: HZN NmyN O// H2N H N N \ ”Yo / \ N M.$N Q. HCl (37% in water) K/ \\ —-—-—-———-> N:kN LQ NaF, MeOH g/NH NaF (91 mg; 2.18 mmol) was added to a solution of W-1 (210 mg; 0.44 mmol) in HCl 37% in water (15 mL) and MeOH (10 mL). The mixture was stirred at 40°C for 16h.

The mixture was cooled to RT and a 10% aqueous solution of K2C03 was added until basic pH. The aqueous layer was saturated with K2C03 powder and the product was 2012/072090 extracted with DCM/MeOH (95/5) (3 times). The combined organic layers were dried over M9804, filtered and the solvent was removed under reduced pressure. The crude was puriﬁed by preparative LC (irregular SiOH 15-40um, Merck 10g, mobile phase DCM/MeOH/NHgaq 93/3/0.1 to 85/15/1). The fractions containing pure compound were combined, the t was removed in vacuo and the title compound was dried in vacuo for 16 h at 60°C to give 9.8 mg of Compound 9 (6%) as a pale brown solid. mp. >260°C.

Overall Scheme in the re aration of final roducts: Method 5 “H2 NH2 >LoiNJOL§\ N/ MeOH N N I N>—\ N / / BOC20 N / / Cl/KN B ——-—')r Cl/KN I N>_O\ DMAP,THF *JNINyO kQ ﬂ mh© B(OH)2 :K/IE H HCI 6N N N N / / N ——'—_> o I >=O suzuki coup "‘9 @l‘ N “l ® N “l : : S nthesis of intermediate Y1: NHz NH2 N/ MeONa/MeOH *1»er\ A I \H’ on N N Cl \N N Sodium methoxide (30wt% in MeOH) (15.6mL, 84.172 mmoi) was added drop wise to a mixture of X1 (synthesis described in Bioorg. Med. Chem, 11, 2003, 5501—5508) (5.7 g, 16.834 mmol) in MeOH (150 mL) at RT. The mixture was stirred at 60°C for 6 h and then cooled down to RT. The precipitate was filtered off and dried, to yield 3.25 g of Y1. The crude compound was used in the next step.

HPLC Rt (min) = 5.53 ; MS M+ (W): 290—292 (method v2003v2002) S nthesis of intermediate Z-1: NHZ ioiNiA N/ / CIXN I N\>_o B0620 N N/ / N i \>—o DMAP, THF * KO N Cl N Boc20 (3.0 9, 13.806 mmol) was added under a N2 flow to a mixture of Y-1 (1.0 g, 3.452 mmol), DMAP (42 mg, 0.345 mmol) in THF (10mL) at RT. The mixture was stirred at 80°C for 2h. The mixture was poured into water and extracted with EtOAo.

The organic layer was washed with water, dried over M9804, filtered and the solvent was evaporated. The crude was ed by preparative LC on (irregular SiOH 20- 45pm 4509 MATREX). Mobile phase (Gradient from 98% DCM, 2% AcOEt to 95% DCM, 5% AcOEt) to afford 0.825 g of Z1 (49% yield, MP = 159°C).

HPLC Rt (min) = 4.43 ; MS M+ (i-r): 490-492 (method V2015V2007) S nthesis of intermediate B-2: Q. 5:4 >LELEL>L J80 >5114.91..

I N\>——o / I N\>_O/ suzuki coupling N I N N \ \N Z-1 U8-2 A solution of Z-1 (300 mg, 0.612 mmol), A—2 (255 mg, 0.918 mmol) and NaHC03 (257 mg, 3.06 mmol) in dioxane/water (4/1) (3 mL) was degassed by bubbling N2 for min. Tetrakis-(triphenylphosphine)—Paiiadium (142 mg, 0.122 mmol) was added and the mixture was d at 100°C for 5h. Water and EtOAc were added and the layers were decanted. The aqueous layer was extracted with EtOAo. The organic layers were combined, dried over MgSO4, filtered and the solvent was evaporated in the next step without further puriﬁcation.

S nthesis of final Com ound 23: N H2 N/ / N HCI 6N N / | >=0 \ N dioxane \ N \ \ “1/ij KG N/N H \\© 8-2 23 HCI 6N (10 mL) was added to a solution of 8-2 (0.7 g, 1.15 mmol) in dioxane (7 mL) at 0°C. The mixture was stirred at RT for 12h and then cooled down to 0°C and basified with K2003. The mixture was extracted with EtOAc+CH30H ). The combined organic layers was dried over M9804, filtered and the solvent was evaporated. The crude was ed by preparative LC on (Stability Silica 5pm 150x30.0mm). Mobile phase (Gradient from 0.3% NH4OH, 97% DCM, 3% MeOH to 1.4% NH4OH, 86% DCM, 14% MeOH), to yield 67 mg of final nd 23 after crystallization from CH30H (19% yield).

Overall Scheme in the re aration of final roducts: Method6 NH2 NH2 I”\>—o’ HoieN Cl \N N @ “ﬂ HetArB(OH)2- Boozo N/ N I N\>_OH —“‘"‘" I I ‘HH @ “ DMAP, THF \ N suzuki coupling c: N NEta \\© KO WO 68438 S nthesis of intermediate C—2: NH2 NHz N HCl 6N N/ / N ClkN I \>—0 I \ 0H N * N>— ‘ Cl N Y-1 C—2 : A mixture of Y-1 (0.53 g, 1.829 mmol) in HCl SN (5 mL) and dioxane (5 mL) was stirred at RT for 18h. The precipitate was filtered off, washed with the minimum of cold dioxane and dried to afford 0.28 g of crude 02 which was used in the next step without further puriﬁcation.

HPLC Rt (min) = 4.96 ; MS M+ (H+): 276—278 (method v2003v2002) S nthesis of intermediate D-2: N/ N>— B0020 N * I \ OH N / k I \>_0H 0 N DMAP, THF C, N D2 :> NEtg (0.187 mL, 1.345 mmol) and then 80020 (0.215 g, 0.987 mmol) were added to a mixture of C2 (0.28 g, 0.897 mmol) and DMAP (11 mg, 0.0897 mmol) in THF (3 mL) at RT. The mixture was stirred at 80°C for 2h. Water and EtOAc were added. The layers were ed. The organic layer was dried over M9804, filtered and the solvent was evaporated to yield 0.18 g of intermediate D-2. The crude compound was used directly in the next step.

HPLC Rt (min) = 6.31 ; MS M+ (H+): 376-378 (method V2002V2002) ~28- S nthesis of final Com ound 20: (i3H mix° UB‘\ NH2 E-2 n N N/ * i \>—o/ ' >=O suzuki coupling 0 N N Cl N N \\© \ I A solution of D2 (240 mg, 0.64 mmol), E—2 (107 mg, 0.96 mmol) and NaHCO3 (269 mg, 3.2 mmol) in e/water (4/1) (3.2 mL) was degassed by bubbling N2 for 10 min. Tetrakis-(triphenylphosphine)—Palladium (148 mg, 0.13 mmol) was added and the mixture was stirred at 100°C for 16h. Water and EtOAC were added and the layers were decanted. The aqueous layer was extracted with EtOAc. The organic layers were combined, dried over M9804, filtered and the solvent was evaporated. The crude was purified on a reverse phase to yield 13 mg of final Compound 20 (6% yield).

Overall Scheme in the re n of final roducts: Method 7 o o XH >L JL JL>k Haw o N o H N ————-—-—-——>~ N/ / A |>=O k I N\>—O x: N,C N x \N 0' N KC 69 @ S nthesis of final Com ound 36: xiis: 3 I' Q N kg @ 2012/072090 A mixture of Z—1 (300 mg, mol) and pyrazole (417 mg, 6.123mmol) was stirred at 180°C for 1h (microwave biotage). The crude compound was purified by chromatography over silicagel column (15-40 pm, 25 g) in CH2C12/MeOH/NH4OH 96/4/05 to give, after crystallization in diisopropylether and drying under vacuum pressure at 80°C, 85 mg of final compound 36.

Overall Scheme in the re aration of final roducts: Method 8 S nthesis of intermediate G-2: SN|%\OHTFHNOafuming OH F-2 G-2 A solution of F—2 (50 g, 316.09 mmol) in TFA (210 mL) was stirred at RT for 30 min.

The mixture was cooled to 5°C then HNOg fuming (19.5 mL, 426.73 mmol) was added drop wise at 5°C. The temperature was maintained at 10-15°C during the addition.

The ice bath was removed and when the ature reached 20°C, a t exothermic event occurred (from 20°C to 45°C in 5 seconds). The mixture was d at RT for 16h. The mixture was poured into a mixture of water and ice. The precipitate was filtered off and washed with water. The precipitate was dried under vacuum at 50°C to give 42 g (65% yield) of intermediate G—2. This intermediate was directly used in the next step without any further cation.

S nthesis of intermediate H-2: POCla N02 N,-Ndimethyl \ i / \s aniline s N Cl G-2 H-2 N,N-dimethylani|ine (76.7 mL, 0.61 mol) was added drop wise to POCI3 (93.7 mL, 1.01 mol) at 0°C. G-2 (41 9, 201.79 mmol) was added portion wise at 0°C then the mixture was warmed to 100°C for 2h. The solution was concentrated under vacuum and the residual POCI3 was removed by azeotropic evaporation with toluene (3 times). The ing oil was taken up in a solution of CH2Cl2-Heptane (70—30) and was filtered through a glass ﬁlter of SiOz. The filtrate was concentrated and the e was puriﬁed by preparative LC on (irregular SiOH 20-45 pm 1000 g DAVISlL), mobile phase (80% Heptane, 20% CH2Cl2). The pure fractions were collected and concentrated to give 37.8 g (78% yield) of intermediate H-2. 8 nthesis of intermediate l—2: N \ NH3 2M/iPrOH \s)L / EtsN i; N CI THF A solution of NH3 2M in iPrOH (115 mL, 229.31 mmol) was added drop wise to a on of H-2 (36.7 9, 152.87 mmol) and Eth (23.4 mL, 168.16 mmol) in THF (360 mL) (the temperature was maintained at RT with an ice—water bath during the addition). The reaction mixture was stirred at RT for 5h. The mixture was evaporated to dryness. Water and EtOAc were added to the residue. The layers were separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layers were dried over M9804, ﬁltered, and the solvent was removed under reduced pressure to give 34.5 g (100% yield) of intermediate l-2.

S nthesis of intermediate J—2: \i :V00Et3N THF \iEE:*0“ J-2 Ethyl chloroformate (13.5 mL, 138.90 mmol) was added to a solution of l-2 (39.8 9, 126.27 mmol) and Eth (26.5 mL, 189.40 mmol) in THF (1300 mL). The e was stirred at RT for 6h and the solvent was partially evaporated under reduced re.

The e was taken up in CHZClz and water. The layers were separated; the aqueous layer was extracted with CH2C|2 ). The combined organic layers were dried over M9804, filtered and the solvent was removed under reduced pressure. The residue was ed by preparative LC on (irregular SiOH 20—45 pm 1000 g DAVISlL), WO 68438 2012/072090 -31 _ mobile phase (gradient from 85% heptane, 15% AcOEt to 80% heptane, 20% AcOEt).

The pure fractions were ted and concentrated to give 35 g (95% yield) of intermediate J-2.

S nthesis of intermediate L—2: CI K2CO3 Nal NO2 N02 N \ NI \ acetone A \ i / / S N N A O \ O O o o Br 0 J K—Z L-2 J-2 (5 g, 17.0 mmol), K-2 (3.91 g, 17.0 mmol), K2003 (5.90 g, 42.7 mmol) and Nal (2.56 g, 17.0 mmol) in acetone (130 mL) were stirred at RT for 18 h. The solution was filtered and the filtrate was evaporated under reduced pressure. The crude compound was purified by preparative LC (irregular SiOH 15-40 pm, 120 g merck, solid sample, mobile phase : heptane/EtOAc 100/0 to 80/20) to give intermediate L-2 as a pale yellow solid (69% yield).

S nthesis of intermediate M-2: (:1 N H2 nN02 N02 NH3 (7 M in MeOH) h N/ \s / \s N N N A at O O O 0 The reaction was done in two batches of 2.7 g of L-2.

Here is the protocol for one batch of 2.7 g: In a sealed tube, L-2 (2.70 g, 6.12 mmol) was stirred in NH3 (7 M in MeOH) (50 mL) and THF (50 mL) at RT for 2 h.

The two batches were mixed.

The mixture was evaporated in vacuo and the e was dried by azeotropic distillation with EtOH (twice) to give a yellow solid. Water and EtOAC were added, the layers were separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layers were dried over M9804, filtered and evaporated in vacuo to give 4.9 g of intermediate M-2 as a yellow solid (90% yield). 8 nthesis of intermediate N-2: NH2 NH2 NO2 N02 N \ N \ mCPBA \s)L / ('D'JL N N \ﬁ N/ N ¢§L\ CHzcb o o o o O O/ J o 0/ N2 mCPBA (1.46 g, 5.93 mmol) was added portionwise to a solution of M-2 (1 g, 2.37 mmol) in CHZCIZ (60 mL) at 0°C. The mixture was stirred at RT for 20 h. An aqueous solution of Na28203 was added to the mixture. The layers were ted and the aqueous layer was extracted with CHgClz (twice). The combined organic layers were washed with a saturated aqueous on of Nchog, dried over M9804, filtered and the solvent was d under reduced pressure to give 980 mg of intermediate N-2 as a yellow solid (91% yield). Intermediate N-2 was used in the next step without further puriﬁcation.

S nthesis of intermediate 0-2: N NH 2 N02 _\ \ISIAN/O NI \ \ NH N \ N N i / u 4;\ /“N N N o :9 9 J O O O/ 2??J o o/ N-2 O-2 A mixture of N—2 (500 mg, 1.10 mmol) and pyrazole (750 mg, 11.0 mmol) was stirred at 80°C for 45 min. The resulting mixture was take up with EtOAc and 1 M aqueous solution of HCI. The layers were separated, the c layer was dried over M9804, filtered and dried in vacuo to give 550 mg of a yellow solid. The crude compound was purified by ative LC (irregular SiOH 15—40 pm, 25 9 Grace, solid sample, mobile phase gradient : from CH2Cl2/MeOH/NH3aq 97/13/003 to 80/20/0.3) to give 370 mg of intermediate 0-2 as a white solid (76% yield).

S s of final Com ound 37: NH2 NH2 \ H NI H N/ l > O g\N N N N / A / N N water i o o 0 Oz’ Fe (280 mg, 5.01 mmol) was added to a mixture of 0-2 (365 mg, 827 umol) in AcOH (17 mL) and water (1.8 mL). The mixture was stirred vigorously at RT for 64 h. The reaction mixture was filtered on a pad of celite, concentrated in vacuo and co- evaporated with toluene (twice) to give a dark residue. The crude was purified by preparative LC (irregular SiOH 15-40 pm, 25 g Merck, solid sample, mobile phase gradient: from CHZCIZIMeOH/NHgaq 4 to 80/20/3) to give 250 mg of a white solid, which was purified again by preparative LC (irregular SiOH 15—40 pm, 25 g Merck, solid sample, mobile phase gradient: from CHZCIZIMeOH/NHsaq 96/4/04 to 80/20/3) to give 110 mg of fraction 1 as a white solid (36%) and 25 mg of fraction 2 as a white solid (8%). Global yield: 45%. 8 mg of on 2 were dried in vacuo for 16 h at 40°C to give 6 mg of final compound 37 as a white solid.

S nthesis of final Com ound 38: NH2 NH2 LINH H N/ N N >=O 0 * I >=O O / LiOH/THF/water /i‘ N N o /t‘ N OH /N /N 37 38 LiOH (9 mg, 123 pmol) was added to a suspension of 37 (15 mg, 41.1 pmol) in THF (4 mL) and water (5 mL). The reaction mixture was d at RT for 16 h. A 10% aqueous solution of K2C03 was added until basic pH. The aqueous layer was saturated with KzCO3 powder and the t was extracted with CHZClleeOH (9/1) (3 times). The combined organic layers were dried over M9804, ﬁltered and the solvent was removed under reduced pressure to give 200 mg. The crude was ed by preparative LC on (X-Bridge-C18 5pm 30*150mm, mobile phase: gradient H20 (0.1% Formic Acid)/MeCN 90/10 to 0/100) to give 12 mg of final compound 38 as a white solid (83%).

S nthesis of final Com ound 39: NH2 NHz H H N/ N A I >=0 N/ 0 A I \ >=o N / Dibal—H in toluene / l“ N N O / 1 N OH THF /N 37 39 Dibal-H (1.2 M in toluene) (0.2 mL, 240 umol) was added dropwise to a solution of 37 (30 mg, 82.1 umol) in THF (3 mL) and toluene (1 mL) under en at 0°C. The solution was stirred at 0°C for 2 h. Dibal-H (0.2 mL, 240 umol) was added and the solution was stirred at RT for 2 h. A saturated aqueous solution of potassium sodium tartrate was added to neutralize the reaction. The e was diluted with EtOAc, followed by ng vigorously for 30 min. The organic layer was separated from the aqueous layer, washed with brine, dried over M9804, ﬁltered and concentrated in vacuo to give 40 mg. The crude was puriﬁed by preparative LC (irregular SiOH 15-40 pm, 4 9 Grace, solid sample, mobile phase gradient : from CH2Cl2/MeOH/NH3aq 96/4/004 to 2) to give a white solid. The afforded white solid was dried in vacuo for 16 h at 40°C to give 8 mg of final compound 39 (29%) as a white solid.

S nthesis of final Com ound 40: NH2 NH: H H L! NH2 N N N/ N/ /\O/H\0/\ n A ] N>=o HE.

N/ L N>=o I )=0 OH ———-—> «R | / If! / N B _,r k / I / N N N é_o /N ACOH /N NEH I /N ﬁllO 39 (45 mg, 133 umol) was solubilized in HBr (30% in AcOH) (10 mL). The mixture was stirred at RT for 1h. The solvent was evaporated and AcOH was azeotropically distilled with toluene (twice) to give 75 mg of intermediate P-2 as a brown solid, which was used for the next step t further purification.

To a suspension of NaH (53 mg, 1.33 mmol) in THF (4 mL) was added dropwise diethyl phosphite (0.130 mL, 1.33 mmol) at RT. The e was stirred at RT for 1 h.

To the mixture was added a solution of P-2 (64 mg, 133 umol) in THF (4 mL). The mixture was d at RT for 16 h. To a suspension of NaH (53 mg, 1.33 mmol) in THF (4 mL) was added dropwise l phosphite (0.130 mL; 1.33 mmol) at RT. The resulting mixture was added to the reaction mixture. The resulting reaction mixture was stirred at RT for 1 h. Water and EtOAc were added, the layers were separated and the organic layer was washed with an aqueous solution of NaHC03 and brine, dried over M9804, filtered and concentrated in vacuo to give 75 mg of a clear oil. The crude was purified by preparative LC (irregular SiOH 15-40 pm, 25 g Merck, dry loading, mobile phase gradient: from CHZClz/MeOH 100/0 to 85/15) to give 38 mg of a white solid, which was triturated in pentane. The resulting solid was ﬁltered and dried in vacuo for 16 h at 50°C to give 28 mg of final compound 40 as a white solid (40% yield).

S nthesis of final Com ound 41: R NHZ >=o L H A | N o N/ \ I /"‘ HCI </:rl1 N N ii—O NXN I >=o OH N I /N 0 Cl/N ﬁﬁ—OHO 40 41 40 (590 mg, 1.29 mmol) was solubilized in HCI (37% in water) (60 mL). The mixture was stirred at 100°C for 16 h. The solvent was ated and H20 was azeotropically distilled with EtOH (twice) to give 605 mg of final compound 41 as a white solid (100% yield).

Table 1. Compounds of formula (I).

Mass LCMS Ret Exact Synthesis STRUCTURE Found Time, (°C) H NMR Mass method [M+H] Method 1H NMR (600 MHz, DMSO-de) 8 ppm 0.84 (br. 5., 2 H), 0.99 (d, J=6.7 Hz, 2 H), 2.00 (br. s., 1 H), 3.16 (br. s., 1 H), 347.15 348 1.01.8 1,2 .03 (br. s., 2 H), 7.08 — 7.21 (m, 2 H), 7.24 - 7.35 (m, 3 H), 7.36 - 7.45 (m, 3 H), 11.51 (br. s., 1 H) 1H NMR (400 MHz, DMSO-de) 6 ppm .08 (s, 2 H), 7.04 (br. s., 2 H), 7.29 (m, J=7.3 Hz, 1 H), 7.34 (t, J=7.3 Hz, 2 H), 383.15 384 1.18,B 7.40 - 7.48 (m, 3 H), 7.49 - 7.56 (m, 2 H), 7.97 (d, J=7.3 Hz, 2 H), 8.20 (s, 1 H), 11.28 (s, 1 H) 1H NMR (DMSO—ds z): 5 ppm 14.45 (br. 3., 1H), 11.49 (s, 1H), 7.54 (s, 1H), 7.41 (d, J=8 Hz, 2H),7.31 (t, J=8 375.18 376 Hz, 2H), 7.28 (t, J=8 Hz, 1H), 7.14 (br. 5., 2H), 5.06 (s, 2H), 3.15 (m, 1H), 2.08- 2.06 (m, 2H), 1.74- 1.621m,6H) Mass LCMS Ret MP Exact Synthesis STRUCTURE Found iTime, (°C) H NMR Mass method [M+H] Method 1H NMR (DMSO-de ,400MH2): 8 ppm 12.34(br.s.,1H), 1.87, 10.32 (br. s., 1H), 307.12 308 2 > 260 V3018V3001 7.22 — 7.44 (m, 5H), 7.18 (s, 1H), 7.01 (s, 1H), 6.48 (br. s., 2H), .00_js_,Z_H)___ 1H NMR (DMSO-c16 ,500MHZ): 5 ppm 11.89 (br. s., 1H), .24 (br. s., 1H), 2.35, 361.16 362 > 260 7.21 — 7.40 (m, 5H), V3018V3001 6.51 (br. 5., 2H), 5.01 (s, 2H), 2.24 (s, 3H), 1.72 - 1.80 (m, 1H), 0.65 - 0.78 m, 4H 1H NMR (DMSO-de ,500MHZ): 8 ppm 11.85 (br. s., 1H), .26 (s, 1H), 7.21 - 2.52, 7.39 (m, 5H), 6.51 375.18 376 > 260 V3018V3001 (br. 5., 2H), 5.02 (s, 2H), 2.65 (m, 2H), 1.78 (br. s., 1H), 1.17 (t, J=6.5 Hz, 3H), 0.65—0.78 m, 4H 1H NMR da ,500MHZ): 5 ppm 11.98 (br. 5., 1H), 2.1, 335.15 336 230 10.27 (s, 1H), 7.20 - 3001 7.40 (m, 5H), 6.40 (s, 2H), 5.01 (s, 2H), 1 2.10 (br. 5., 6H) 1H NMR (500 MHz, DMSO-de) 8 ppm 321.13 322 12.00 - 12.17 (m, V3018V3001 1H), 10.29 (s, 1H), 7.35 - 7.40 (m, 2H , 2012/072090 Synthesis STRUCTURE Mass method 7.32 (t, J = 7.41 Hz, 2H), 7.23 - 7.29 (m, 1H), 6.66 - 6.90 (m, 1H), 6.44 (br. 5., 2H), .00 (br. 5., 2H), 2.10 — 2.26 (_m_,3H). 1H NMR (400 MHz, DMSO-de) 5 ppm .38 (br. 5., 1H), 8.56 (br. 5., 1H), 7.71 2.47, 322.13 323 > 260 (d, J = 7.07 Hz, 1H), V3018V3001 7.09 - 7.30 (m, 4H), 6.45 (br. 5., 2H), 4.99 (s, 2H), 1.25 (br. 5., 1H NMR (500 MHz, MeOD) 6 ppm 6.83 (s, 1H), 3.95 (dd, J= 2.84, 11.35 Hz, 2H), 3.87 (d, .1 = 7.57 Hz, 2H), 3.36 - 3.44 (m, 1.86, 355.18 356 > 260 2H), 2.25 — 2.37 (m, V3018V3001 1H), 1.89 — 1.98 (m, 1H), 1.60 (dd, J: 1.89, 12.93 Hz, 2H), 1.41 - 1.52 (m, 2H), 0.88 - 0.96 (m, 2H), 0.71 - 0.77 m, 2H . 1H NMR (DMSO-d6 ,500MHz): 6 ppm .47 (br. 5., 1H), 7.22 - 7.38 (m, 5H), 2.11, 7.20 (s, 1H), 6.91 (s, 11 365.16 366 > 260 V3018V3001 1H), 6.62 (br. 5., 2H), 4.97 (s, 2H), 4.52 (t, J=5.4 Hz, 2H), 3.48 (t, J=5.4 Hz, 2H), 3.10 (s, 3H) "_'—_——_—_T—"——'—— Mass LCMS Ret MP Exact Synthesis STRUCTURE Found ime, (°C) H NMR Mass method [M+H] Method 1H NMR (DMSO—da ,500MHz): 6 ppm 7.16 - 7.33 (m, 5H), 2.06, 12 321.13 322 > 260 7.10 (s, 1H), 6.84 (s, V3018V3001 1H), 6.24 (br. s., 2H), 4.91 (s, 2H), 3.85 (s, 1H NMR (DMSO-d6 ,300MHz): '6 ppm .25 (br.s, 1H), 9.47 (s, 2H), 9.23 (s, 1H), 7.40 (t, J=7.2Hz, 2H), 319.12 320 2.3, Villa 7.34 (t, J=7.2 Hz, 2H), 7.27 (d, J=7.2 Hz, O (s, 2H), .75 (s, 1H), 5.02 (s, 1H NMR (DMSO-de ,300MHz): 6 ppm 11.10 (br. s., 1H), .20 (br. 5., 1H), 7.43 (d, J=7.1Hz, 2H), 7.33 (t, J=7.1 18 306.12 307 2.45, Villa Hz, 2H), 7.26 (t, J=7.1 Hz, 1H), 6.83 (d, J=1.5 Hz, 1H), 6.68 (br. s., 1H), 6.35 (s, 2H), 6.10 (d, J=1.5 Hz, 1H), 4.98 (g 2H) 1H NMR (DMSO-d6 ,300MHz): 6 ppm 12.97 (br. s., 1H), 307.12 308 1.82, Villa 10.25 (br. s., 1H), 8.02 (br. s., 2H), 7.18 - 7.44 (m, 5H), 6.42 (s, 2H), 4.9515, 2H) W0 20131068438 Mass LCMS Ret MP Exact # STRUCTURE Found LTime, Synthesis (°C) H NMR Mass method [M+H] Method 1H NMR (DMSO-de ,300MHz): 6 ppm HZN H 10.60 (br. s., 1H). 7.76 (br.s, 1H), 7.19 — ~~ >0 307.11 308 2.57, Villa 7.40 (m, 5H), 7.00 (d, \\ J=3.3 Hz, 1H), 6.66 (s, 2H), 6.59 (dd.

J=3.3, 1.8 Hz, 1H), .0 s, 2H 1H NMR (500 MHz, DMSO-de) 6 ppm H2N n 12.84 - 13.37 (m, N/\ T 2.03, 1H), 10.30 (br. 3., 23 . ~~ >6 307.12 308 > 260 Nb V3018V3001 1H), 7.23 - 7.76 (m, 6H), 6.70 (br. s., 1H), 6.49 (br. s., 2H), 4.98 s, 2H . 1H NMR (DMSO-ds z): 8 ppm 12.25 (br. s., 1H), HZN n H 7.18 (d, J=8.1 Hz, 2.20 24 ref” 1H), 6.99 - 7.14 (m, 362.16 363 240 RN” V3018V3001 4H), 6.50 (s, 2H), 4.94 (s, 2H), 3.93 (s, 2H), 3.01 — 3.07 (m, 2H), 2.72 (t, J=5.6 ”2&2 1H NMR (DMSO-ds ,4OOMHz): 6 ppm 12.13 (br. s, 1H), .38 (br. s, 1H), HaN H 8.15 (br. 5., 0.49 H, Nib)”_ NV “Q 2.47 formate salt pic), ‘ :N 390.19 391 196 .2 V3018V3001 7.39 (br. s., 1H), 7.18 - 7.34 (m, 3H), 7.09 (br. s., 2H), 6.50 (br. 3., 2H), 5.01 (br. s., 2H), 3.71 (br. s, 2H), 2.50 — 2.61 (m, 4% WO 68438 PCT/EP20121072090 Mass LCMS Ret MP Exact Synthesus.

# STRUCTURE Found Time,_ (°C) HNMR Mass method [M+H] Method 1.67 (br. s., 4H) 1H NMR (DMSO-de, 400MHz) : 5 ppm 12.05 (5 br, 1H), .27 (s, 1H), 8.56 (d, J: 1.8 Hz, 1H), 8.15 (s, 0.59H, QR): 1,40 formate salt pic), N7 ”\,O— 1,90 7.70 (dd, J: 8.2, 1.8 26 ~ Vs,:NH 362.16 363 4 > 260 0.1-.ch V3018v3001 Hz. 1H), 7.20 (d, J = 8.2 Hz, 1H), 6.93 (3 br, 1H), 6.49 (5 br, 2H), 4.97 (s, 2H), 2.41 (s, 3H), 1.78- 1.90 (m, 1H), 0.70- 0.87 (m, 2H), 064- um, 2H) 1H NMR (DMSO—de ,500MH2): 5 ppm 1037 (s, 1H), 7.23 - 7.38 (m, 5H), 7.21 (d, J=0.9 Hz, 1H), 6.91 1.78 27 1142‘“~ \,<> (d, J=0.9 Hz, 1H), 351.14 352 2 260 {in V3018v3001 6.58 (br. s., 2H), 4.96 (s, 2H), 4.81 (t, J=5.7 Hz, 1H), 4.41 (t, J=5.7 Hz, 2H), 3.59 (q, J=5.7 Hz, 2H) 1H NMR (DMSO-ds HZN H ,500MH2): 5 ppm Nﬁﬁnﬁ 11.78 - 12.24 (m, ,Ef-N \—© 2 51' 28 363.18 364 2 > 260 1H), 10.23 (s, 1H), $34. V3018V3001 7.07 - 7.47 (m, 5H), 6.21 - 6.93 (m, 3H), .01 (s, 2H), 1.13 - Mass LCMS Ret MP Exact Synthesis STRUCTURE Found H NMR Mass Fime, (°C) method [M+H] Method 1.45 (m, 9H) 1H NMR (DMSO-de z): 6 ppm 11.80 - 12.14 (m, 1H), 10.41 (br. s., 1H), 7.08 - 7.70 (m, 2.35 29 /L::N N 349.17 350 > 260 5H), 6.65 - 6.89 (m, V3018V3001 1H), 6.37 - 6.62 (m, 2H), 4.89 - 5.21 (m, 2H), 2.73 — 3.16 (m, 1H), 1.04 - 1.31 (m, __~T__ 1H NMR (011180-816 ,500MHz): 6 ppm 11.82 - 12.28 (m, 1H), 10.47 (br. s., ”if“ 1H), 7.08 — 7.56 (m, 2.18 335.15 336 > 260 5H), 6.63 - 7.01 (m, V3018V3001 1H), 6.38 — 6.59 (m, 2H), 4.78 — 5.07 (m, 2H), 2.53 - 2.69 (m, 2H), 0.95 - 1.35 (m, 1H NMR (DMSO-de ,500MHz): 5 ppm 13.07 (br. 5., 1H), .46 (br. 8., 1H), 2.38 7.83 (s, 1H), 7.39 (d, 31 FWﬁ: 375.11 376 > 260 V3018V3001 J=8.2 Hz, 2H), 7.32 (t, J=8.2 Hz, 2H), 7.28 (t, J=8.2 Hz, 1H), 8.85 (br. s., 2H), 4.98 s, 2H W0 20131068438 Mass LCMS Rat MP Exact STRUCTURE Ll'ime, Synthesis Found (°C) H NMR Mass method [M+H] Method 1H NMR (DMSO-ds ,500MHz): 6 ppm .44 (br. s., 1H), 2.06 32 308.10 309 8.45 (s, 1H), 7.63 (s, V3018V3001 1H), 7.16 - 7.37 (m, 5H), 6.70 (br. 3., 2H), 4.96 (s, 2H) 1H NMR (DMso—d6 z): 5 ppm .72 (br. s., 1H), 2.23 33 323.11 324 > 250 7.11 - 7.56 (m, 5H), ‘V3018V3001 6.94 (br. s., 2H), 5.00 (br. s., 2H), 2.41 (s, 1H NMR (DMSO—d6 z): 6 ppm .71 (br.s.,1H), 2.27 7.16 - 7.49 (m, 5H), 34 367.14 368 > 250 V3018V3001 6.96 (br. s., 2H), 5.01 (s, 2H), 3.72 (t, J=6.3 Hz, 2H), 3.24 (s, 3H), 3.01 (t, J=6.3 Hz, 2H) 1H NMR (DMSO—de ,500MHz): 6 ppm .31 (br.s.,1H), 2.42 8.24 (s, 1H), 7.51 (s, 321.13 322 > 260 V3018V3001 1H), 7.18 - 7.40 (m, 5H), 6.78 (br. s., 2H), 4.96 (s, 2H), 2.08 (s, 1H NMR (DMSO-de ,500MHz): 5 ppm .33(br.s.,1H), 8.46 (d, J=2.5 Hz, 2.25 36 307.12 308 > 260 1H), 7.70 (s, 1H), V3018V3001 7.20 - 7.40 (m, 5H), 6.82 (br. s., 2H), 6.48 (d, J=3.8 Hz, 1H), 4.97 {3, 21-_1) Mass LCMS Ret MP Exact Synthesis STRUCTURE Found 1Time, (°C) H NMR Mass method [M+H] Method 1H NMR (DMSO-de ,400MHz): 6 (ppm) 9.80 (br. 5., 1H), 8.47 (d, J=2.5 Hz, 1H), HZN H N 7.99 (s, 1H), 7.87 (d, 2.24 J=7.6 Hz, 1H), 7.70 N):N V3018V30 (s, 1H), 7.65 (d, 37 Cw 365.12 366 J=7.6 Hz, 1H), 7.50 o O_1_ o (t, J=7.6 Hz, 1H), 6.84 (br. s, 2H), 6.43 - 6.63 (m, 1H), 5.04 (s, 2H), 3.83 (s, 3H) 1H NMR (DMSO-ds ,400MHz): 6 (ppm) 13.01 (br.s.,1H), .46 (br. 3., 1H), 2.27 8.47 (s, 1H), 7.95 (s, 1H), 7.84 (d, J=7.6 Hz, 1H), 7.69 (s, 1H), 38 351.11 352 332 g; 7.60 (d, J=7.6 Hz, 1H), 7.46 (t, J=7.6 Hz, 1H), 6.87 (br. s., 2H), 6.48 (s, 1H), .03 (s, 2H) H NMR (DMSO-de ,500MHZ): 6 (ppm) .28 (br. s., 1H), 8.46 (s, 1H), 7.70 (s, 1.87 1H), 7.10 - 7.37 (m, 4H), 6.82 (br. s., 2H), V3018V300 6.35 - 6.57 (m, 1H), 39 337.13 338 1 5.17 (t, J=5.7 Hz, 1H), 4.96 (s, 2H), 4.45 (d, J=5.7 Hz, LCMS Ret Synthesis STRUCTURE H NMR method H NMR (DMSO-da 500MHz): 8 (ppm) .41 (br.s.,1H), 8.46 (br. s., 1H), 7.69 (s, 1H), 7.04 - 7.38 (m, 4H), 6.85 (br. s., V3018V3OO 2H), 6.47 (br. 3., 1H), 40 457.16 458 218 1 4.95 (br. s., 2H), 3.85 (quin, J=7.0 Hz, 4H), 3.18 (d, J=21.4 Hz, 2H), 1.06 (t, J=7.0 Hz, 6H) H NMR (DMSO-ds ,400MHz): 5 (ppm) .43 (s, 1H), 8.46 (d, J=2.5 Hz, 1H), .40 7.69 (s, 1H), 7.10 - 7.31 (m, 4H), 6.84 V2012V200 41 401.10 402 2 101 (br. s., 2H), 6.47 (dd, J=2.5, 1.5 Hz, 1H), 6.29 (br.s, 2H), 4.90 (s, 2H), 2.92 (d, J=21.2 Hz, 2H) H NMR (DMSO—de ,500MHZ); 6 (ppm) .20 (br. 5., 1H), 8.37 (d, J=2.2 Hz, 2.45 1H), 7.65 (s, 1H), 7.48 (d, J=6.9 Hz, V3014V300 1H), 7.19 (t, J=6.9 42 338.12 339 1 Hz, 1H), 6.82 - 7.00 (m, 3H), 6.44 (dd, J=2.4, 1.7 Hz, 1H), 4.95 - 5.14 (m, 2H), 2.43 (s, 3H) 1H NMR (DMSO-de z): 6 (ppm) V3014V300 12.48 - 13.42 (m, 43 347.12 348 1 1H), 9.90 - 10.57 (m, 1H), 8.44 (d, J=9.1 Hz, 1H), 7.37 - 7.99 ~46- Mass LCMS Ret MP Exact _ . SyntheSIS STRUCTURE Found Ime, (°C) H NMR Mass method [M+H] Method (m, 3H), 7.19 (t, J=9.1 Hz, 1H), 6.83 (t, J=9.1 Hz, 1H), 6.69 (br. s., 1H), 6.47 (br. s., 2H), 5.12 (br. ., 2H) 1H NMR (DMSO-d5 ,400MHz): 6 (ppm) 12.32 - 13.87 (m, 3.05 1H), 9.94 — 10.53 (m, 1H), 7.4 — 8.26 (m, V3014V300 - 6.89 (m, 44 5H), 6.61 365.12 366 1 1H), 6.28 - 6.59 (m, 2H), 5.05 (s, 2H), 3.83 (s, 3H) H NMR (DMSO-de ,4OOMHz): 6 (ppm) 13.06 (br. 5., 2H), .32 (br. 3., 1H), 2. 13 7.97 (s, 1H), 7.83 (d, J=7.6 Hz, 1H), 7.69 300 (d, J=7.6 Hz, 1H), 45 352 7.57 (br. 5., 1H), 7.46 (t, J=7.6 Hz, 1H), 6.72 (d, J=1.5 Hz, 1H), 6.48 (s, 2H), .04 (s, 2H) 1H NMR (DMSO~de ,500MHz): 6 (ppm) 12.48 - 13.52 (m, 1.63 1H), 9.83 - 10.74 (m, 1H), 7.01 - 7.98 (m, V3018V300 5H), 6.22 - 6.84 (m, 46 337.13 338 > 260 1 3H), 5.17 (t, J=5.7 Hz, 1H), 4.97 (s, 2H), 4.44 (d, J=5.7 Hz, Mass LCMS Ret MP Exact Synthesis # STRUCTURE Found ime, (°C) H NMR Mass method [M+H] Method H NMR (DMSO-da ,400MHz): 5 (ppm) HZN H N 10.45 (s, 1H), 7.13 - N/\ N/V/o 7.54 (m, 6H), 6.94 (s, 4271 @ 2.11 1H), 6.62 (br. 5., 2H), Q/N 4.98 (s, 2H), 4.33 — k V3018V300 4.48 (m, 2H), 3.82 — 47 485.19 486 1 4.02 (m, 4H), 1.76 - IP=O 1.92 (m, 2H), 1.47 - /‘0 ‘o 1.66 (m, 2H), 1.15 (t, J=6.8 Hz, 6H) H NMR (DMSO~d5 2): 6 (ppm) .35 (br. s., 1H), 8.27 - 8.53 (m, 2H), H2N n 1.81 7.77 (s, 1H), 7.67 (s, N):\ T0 N‘ \N V3018V300 1H), 7.47 (d, J=9.1 43 \‘g/” / U 347.12 348 1 Hz, 1H), 7.15 - 7.27 /N (m, 1H), 6.76 - 6.88 (m, 3H), 6.36 - 6.53 (m, 1H), 5.09 (s, 2H) ‘H NMR (DMSO-da ,500MHz): 6 (ppm) 9.42 - 10.55 (m, 1H), 8.35 (d, J=2.5 Hz, HZN H N 1.94 \Fo 1H), 8.01 (d, J=5.4 N/\ Hz, 1H), 7.65 (s, 1H), )zN “1% V3018V300 7.02 (d, J=5.4 Hz, 49 OxN ‘” 368.13 369 > 260 0 o— 1H), 6.80 (br. 5., 2H), \ 6.36 - 6.55 (m, 1H), .07 (s, 2H), 3.81 - 3.96 (m, 6H) p ‘H NMR (DMSO-de HZN H 2.78 N ,500MHz): 6 (ppm) N/ 10.31 \ r N (br. s., 1H), V3014V300 8.49 (d, J=8.5 Hz, 50 —-— 322.13 323 8 > 260 1 2H), 7.71 (s, 1H), 7.65 (d, J=7.6 Hz, 1H), 7.21 (d, J=7.6 Hz, 1H), 6.82 (br. s., Mass LCMS Ret MP Exact _ Synthesis STRUCTURE Found Tlme, (°C) H NMR Mass method [M+H] Method 2H), 6.50 (br. s., 1H), 4.95 (s, 2H), 2.39 (s, 1H NMR (DMSO-d6 z): 8 (ppm) 12.36 — 12.99 (m, 2.35 1H), 10.33 (br. 3., 1H), 6.94 — 7.75 (m, V3018V300 5H), 5.99 - 6.73 (m, 347.15 348 > 260 1 3H), 4.97 (s, 2H), 1.81 - 1.97 (m, 1H), 0.54 - 1.02 (m, 4H) 1H NMR (DMSO-de ,400MH2): 8 (ppm) .23 (br. s., 1H), 7.68 (d, J=2.0 Hz, 1.93 1H), 7.15 - 7.40 (m, 5H), 6.72 (d, J=2.0 V3018V300 Hz, 1H), 6.46 (s, 2H), 351.14 352 4.97 (s, 2H), 4.87 1 (t, J=5.1 Hz, 1H), 4.17 (t, J=5.1 Hz, 2H), 3.75 (q, J=5.1 Hz, mMR (DMSO-d6 ,SOOMHz): 8 (ppm) 2.26 12.94 (br. s., 1H), .28 (s, 1H), 7.17 - V3018V300 7.49 (m, 6H), 6.41 321.13 322 192 1 (br. 5., 2H), 4.97 (s, 2H), 2.28 - 2.39 (m, H NMR (DMSO-ds 1.32 ,500MHz): 5 (ppm) 11.90 - 12.42 (m, 435.21 436 W 2 1 1H), 10.14 (br. s., 1H), 7.85 ~ 8.01 (m, LCMS Ret Synthesis STRUCTURE H NMR method 1H), 7.35 - 7.56 (m, 1H), 6.21 - 7.07 (m, 4H), 4.65 - 4.77 (m, 2H), 3.86 - 3.94 (m, 2H), 2.38 - 2.44 (m, 2H), 2.04 (s, 6H), 1.77— 1.89 (m, 1H), 0.60 - 0.92 (m, 4H) 1H NMR (DMSO-dg; ,400MHz): 8 (ppm) 12.52 (br. s., 1H), .32 (s, 1H), 7.59 (s, 1H), 7.46 - 7.51 N .2_-§9__ (m, 1H), 7.34 - 7.45 N/ \ 260 (m, 2H), 7.12 (br. s., 300 2H), 6.49 (s, 2H), 55 N—$11 «\/NH 404.17 405 2 218 4.94 - 5.25 (m, 2H), 0 __ 3.41 (t, J=7.1 Hz, E“) 2H), 3.20 - 3.29 (m, 2H), 1.79 (quin, J=7.1 Hz, 2H), 1.64 (quin, J=7.1 Hz, 2H) 1H NMR (DMSO-d6 ,500MHZ): 6 (ppm) 12.47 (br. s., 1H), .30 (br. 3., 1H), w} 1 \ 8.25 (br. s., 1H), 7.84 /.\( \40 O "\~N‘/L*".,§;_o (d, J=8.2 Hz, 1H), o W 7.13 (br. s., 2H), 6.90 57 bf M 396.13 397 2 >260 ($1111 L (d, J=8.2 Hz, 1H), 6.50 (br. s., 2H), 4.94 (br. 5., 2H), 4.87 (br. s., 2H), 3.63 (s, 3H) 1H NMR (DMSO-ds "‘2N H & \ N L}~@ﬂ0a]. Vﬁo 0H ,500MH2): 8 (ppm) 11.87 — 13.45 (m, v3014v300 58 \N 382.11 (NH 383 2H), 10.50 (br. 3., 1 2 >260 1H), 8.27 (br. s., 1H), 7.83 (d, J=7.6 Hz, 1H), 7.22 (br. s., 2H), W0 20131068438 LCMS Ret MP Exact Synthesis STRUCTURE Found Time, (°C) H NMR Mass method Method 6.86 (d, J=7.6 Hz, 1H), 6.61 (br. 5., 2H), 4.94 (br. s., 2H), 4.77 (br. s., 2H) 1H NMR (DMSO—de ,400MHz): 6 (ppm) 8.98 — 12.14 (m, 11-1), 2.61 8.21 (s, 1H), 6.04 — 7.47 (m, 6H), 4.95 300 (br. s., 2H), 4.02 (br. 60 402.19 403 2 242 1 s., 2H), 3.13 (br. s., 2H), 2.79 (br. s., 2H), 1.67 - 1.97 (m, 1H), 0.42 - 0.94 (m, 4H) ‘H NMR (DMSO-de ,400MH2): 8 (ppm) 11.85 (br. 5., 1H), .32 (s, 1H), 7.09 2.14 (s, 2H), 6.46 (s, 2H), HQN H 3.81 (t, J=7.2 Hz, V3014V3OO 2H), 2.30 — 2.48 (m, 61 385.23 386 2 1 10H), 2.27 (s, 3H), 1.74 (quin, J=7.2 Hz, 2H), 1.49 (quin, J=7.2 Hz, 2H), 1.20 - 1.36 (m, 2H) H NMR (DMSO-de .500MHz): 5 (ppm) 11.91 (br.s.,1H), .29 (br. s., 1H), 1.67 6.84 (br. s., 1H), 6.49 (br. 8., 2H), 3.79 (t, V3018V300 J=6.9 Hz, 2H), 2.52 - 62 410.25 411 2 174 1 2.70 (m, 6H), 1.80 ~ 1.90 (m, 1H), 1.71 (br. 5., 5H), 1.39 - 1.52 (m, 2H), 1.17 - 1.38 (m, 5H), 0.51 - 0.91 (m, 4H) Mass LCMS Ret MP Exact .

URE Found Time,_ Synthesns (°C) H NMR Mass method [M+H] Method H NMR (DMSO-d6 ,400MH2): 6 (ppm) 12.35 (br. s., 1H), .24 (br. s., 1H), Nth3 A311— 7.11 0 (br. s., 2H), 6.44 (s, 2H), 3.78 - 3.87 “f!“ LOO V3014V300 (m'2H>’3'70(d’ 63 31514' 316 2 >260 g/NH" 1 ‘ J=7.1 Hz, 2H), 3.24 (t, J=10.9 Hz, 2H), 1.99 - 2.18 (m, 1H), 1.08 - 1.76 (m, 4H) Analytical Methods.

All compounds were characterized by LC—MS. The following LC-MS methods were used: Method VILLA: All analyses were performed using an t 1100 series LC/MSD quadrupole coupled to an Agilent 1100 series liquid chromatography (LC) system consisting of a binary pump with degasser, autosampier, thermostated column compartment and diode array detector. The mass spectrometer (MS) was operated with an atmospheric pressure electro—spray ionisation (APl-ES) source in positive ion mode. The capillary voltage was set to 3000 V, the fragmentor voltage to 70 V and the quadrupole temperature was maintained at 100°C. The drying gas flow and temperature values were 12.0 L/min and 350°C respectively. Nitrogen was used as the nebulizer gas, at a pressure of 35 psig. Data acquisition was performed with Agilent Chemstation software.

In addition to the l procedure, es were carried out on a YMC pack ODS- AQ C18 column (50 mm long x 4.6 mm i.d.; 3pm particles) at 35°C, with a ﬂow rate of 2.6 mL/min. A gradient elution was performed from 95% (water + 0.1% formic acid)/ % Acetonitrile to 5% (water + 0.1 % formic acid) / 95% Acetonitrile in 4.80 minutes, then the ﬁnal mobile phase composition was held for an additional 1.00 min. The standard ion volume was 2 uL. Acquisition ranges were set to 190-400nm for the UV-PDA detector and 100-1400 m/z for the MS detector.

Method B Y UPLC System with SQD-detector Mobile Phase: A: methanol, B: 10mM Ammonium acetate in 90% water and 10% Acetonitrile Column: Type column: Aquity UPLC BEH C18 1.7um 2.1x50mm Column (Waters No 186002350), Temperature: 70°C. Gradient timetable. Flow: 0.7 ml/min, Acquisition stop: . Stop time: 2 min.

Time Flow (ml/min.) Injection Vol.2 0.75ul. inject Type: Partial Loop With Needle Overfill Start wavelength: 210 nm. End wavelength: 400 nm. Resolution: 1.2 nm. Sampling Rate: 20 points / sec MS—method: Function 1: ion Mode: ES+, Data Format: Centroid Start Mass: 160. End Mass: 1000 Scan time (sec): 0.1, Start Time (min): 0.0, End Time (min): 2.0, Cone Voltage (V): 30 on 2: ion Mode: ES-, Data Format: Centroid, Start Mass: 160, End Mass: 1000 Scan time (sec): 0.1, Start Time (min): 0.0, End Time (min): 2.0, Cone Voltage (V): 30, Flow in MS: 700uI/min W0 2013[068438 General procedure VDR1 (for s V100xV10xx.olp and V200xV20xx.olp) The HPLC measurement was performed using an Alliance HT 2795 (Waters) system sing a quaternary pump with degasser, an autosampler, a diode-array detector (DAD) and a column as specified in the respective methods below, the column is hold at a temperature of 30°C. Flow from the column was split to a MS spectrometer. The MS detector was configured with an electrospray ionization source. The capillary needle voltage was 3 kV and the source temperature was maintained at 100 °C on the LCT (Time of Flight ZsprayTM mass spectrometer from Waters — for methods V100xV10xx.o|p), and 3.15 W at 110 °C on the ZQTM (simple quadrupole ZsprayTM mass spectrometer from Waters - for methods 20xx.olp). Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass nx-Openlynx data system.

General procedure VDR2 (for methods V300xV30xx.olp) The LC measurement was performed using a UPLC (Ultra Performance Liquid Chromatography) Acquity (Waters) system comprising a binary pump with er, an autosampler, a diode-array detector (DAD) and a column as specified in the respective methods below, the column is hold at a ature of 40°C. Flow from the column was brought to a MS detector. The MS detector was configured with an electrospray ionization . The capillary needle voltage was 3 kV and the source ature was maintained at 130 °C on the Quattro (triple quadrupole mass spectrometer from Waters). Nitrogen was used as the nebulizer gas. Data ition was performed with a Waters-Micromass MassLynx—Openlynx data system.

Method V1005V1012 In addition to the general procedure VDR1: Reversed phase HPLC was carried out on a Waters X-bridge C18 column (3.5 pm, 4.6 x 100 mm) with a flow rate of 0.8 .

Two mobile phases e phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile) were employed to run a gradient condition from 80 % A and 20 % B (hold for 0.5 minute) to 90 % B in 4.5 minutes, 90 % B for 4 minutes and reequilibrated with initial conditions for 3 minutes. An injection volume of 5 p] was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds.

W0 2013f068438 Method V1004V1012 In addition to the general procedure VDR1: Reversed phase HPLC was carried out on a Kromasil C18 column (3.5 pm, 4.6 x 100 mm) with a flow rate of 0.85 ml/min. Three mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile; mobile phase C: 0.2 °/o formic acid + 99.8 % ultra—pure Water) were employed to run a gradient condition from 35 % A B and 35 % C (hold for , 30 % 1 minute) to 100 % B in 3 minutes, 100 % B for 4.5 minutes and reequilibrated with l conditions for 3 minutes. An injection volume of 5 ul was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds.

Method V101OV1012 In addition to the general procedure VDR1: Reversed phase HPLC was carried out on a Waters Atlantis C18 column (5 pm, 3.9 X 100 mm) with a ﬂow rate of 0.8 ml/min.

Three mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile; mobile phase C: 0.2% formic acid +99.8% pure water) were employed to run a gradient condition from 50 % A and 50 % C (hold for 1.5 minute) to 10% A, 80 % B and 10% C in 4.5 minutes, hold for 4 minutes and librated with initial conditions for 3 minutes. An ion volume of 5 pi was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds.

Method 2002 + LCpos_court.olp In addition to the general procedure VDR1: Reversed phase HPLC was d out on a Kromasil C18 column (3.5 pm, 4.6 x 100 mm) with a flow rate of 0.8 ml/min. Three mobile phases (mobile phase A: 100 % 7 mM ammonium e ; mobile phase B: 100 "/0 acetonitrile; mobile phase C: 0.2 °/o formic acid + 99.8 % ultra—pure water) were employed to run a gradient condition from 35 % A , 30 °/o B and 35 % C (hold for 1 minute) to 100 % B in 4 minutes, 100 % B for 4 minutes and reequilibrated with initial conditions for 2 minutes. An injection volume of 10 ul was used. Cone e was 20 V for positive and negative ionization mode. Mass spectra were ed by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds. 2012/072090 Method V2003V2002 In on to the general procedure VDR1: Reversed phase HPLC was carried out on a ge C18 column (3.5 pm, 4.6 x 100 mm) with a flow rate of 0.8 . Two mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile; were employed to run a nt condition from 80 % A B , 20 % (hold for 0.5 minute) to 10 % A, 90 % B in 4.5 minutes, hold at 10 % A and 90 % B for 4 minutes and reequilibrated with initial ions for 3 minutes. An injection volume of 10 ul was used. Cone voltage was 20 V for positive and negative ionization mode.

Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds.

Method V2012V2002 In addition to the general procedure VDR1: Reversed phase HPLC was carried out on a Waters Atlantis C18 column (5 pm, 3.9 x 100 mm) with a flow rate of 0.8 ml/min.

Three mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitriie; mobile phase C: 0.2 % formic acid + 99.8 % ultra-pure Water) were employed to run a gradient ion from 50 % A B and 50 % C (hold for , 0 % 1.5 minutes) to 10 % A B and 10 % in 3.5 minutes, hold in these conditions for , 80 % 4 minutes and reequilibrated with initial conditions for 3 minutes. An injection volume of 10 pl was used. Cone voltage was 20 V for positive and negative ionization mode.

Method V2015V2007 In addition to the general ure VDR1: ed phase HPLC was carried out on a Supelco Ascentis Express C18 column (2.7 pm, 3.0 x 50 mm) with a ﬂow rate of 0.7 ml/min. Two mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile) were employed to run a gradient condition from 80 % A and 20 % B (hold for 0.5 minute) to 5% A and 95 % B in 2.5 minutes, hold for 4.5 3O minutes and back to initial conditions in 1.5 minutes and hold for 1 min. An injection volume of 5 ml was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 s.

Method V3018V3001 In addition to the general procedure VDR2: ed phase UPLC was carried out on a Waters Acquity BEH (bridged ethylsiloxane/silica hybrid) C18 column (1.7 pm, 2.1 x 100 mm) with a ﬂow rate of 0.343 ml/min. Two mobile phases (mobile phase A: 95 % W0 20131068438 7 mM ammonium acetate / 5 % acetonitrile; mobile phase B: 100 % acetonitrile) were employed to run a gradient condition from 84.2 % A and 15.8 % B (hold for 0.49 minutes) to 10.5 °/o Aand 89.5 % B in 2.18 minutes, hold for 1.94 min and back to the initial conditions in 0.73 min, hold for 0.73 minutes. An injection volume ot2 pl was used. Cone voltage was 20V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.2 seconds using an lnterscan deiay of 0.1 seconds.

Method V3014V3001 In addition to the general procedure VDR2: Reversed phase UPLC was carried out on a Waters HSS (High Strength ) T3 column (1.8 pm, 2.1 x 100 mm) with a flow rate of 0.35 ml/min. Two mobile phases (mobile phase A: 95 % 7 mM ammonium acetate / 5 % acetonitrile; mobile phase B: 100 % itrile) were employed to run a gradient condition from 99 % A (hold for 0.5 minutes) to 15 % A and 85 % B in 4.5 minutes, hold for 2 min and back to the l conditions in 0.5 min, hold for 1.5 minutes. An injection volume of 2 l was used. Cone voltage was 20 V for ve and negative ionization mode. Mass a were acquired by scanning from 100 to 1000 in 0.2 seconds using an interscan delay of 0.1 seconds.

Biological Activity of compounds of formula (I) Description of Biological Assays Reporter assays for assessment of TLR7 activity (24h) The ability of compounds to activate human TLR7 was assessed in a cellular reporter assay using HEK293 cells transiently ected with a TLR7 or TLR8 expression vector and NFKB-iuc reporter construct. in one instance the TLR expression construct expresses the respective wild type sequence or a mutant sequence comprising a deletion in the second leucine—rich repeat (leR2) of the TLR. Such mutant TLR proteins have previously been shown to be more susceptible to agonist activation (US 7,498,409).

Briefly, HEK293 cells were grown in culture medium (DMEM supplemented with 10% FCS and 2 mM Glutamine). For transfection of cells in 10 cm , cells were ed with Trypsin—EDTA, transfected with a mix of CMV-TLR7 or TLR8 plasmid (750 ng), uc plasmid (375 ng) and a transfection reagent and ted 24 hours or 48 hours respectively at 37°C in a ﬁed 5% C02 atmosphere. ected cells were then detached with Trypsin-EDTA, washed in PBS and resuspended in medium to a density of 1.67 x 105 cells/mL. Thirty microliters of cells W0 2013i068438 were then dispensed into each well in 384-well plates, where 10 uL of compound in 4% DMSO was already present. Following 6 hours incubation at 37°C, 5% 002, the luciferase activity was determined by adding 15 pl of Steady Lite Plus substrate (Perkin Elmer) to each well and readout performed on a ViewLux ultraHTS microplate imager (Perkin Elmer). Dose response curves were generated from measurements performed in quadruplicates. Lowest effective concentrations (LEC) values, defined as the concentration that induces an effect which is at least two fold above the rd deviation of the assay, were determined for each compound. Compound toxicity was determined in parallel using a similar dilution series of compound with 30 uL per well of cells transfected with the R7 construct alone (1.67 X 105 cellslmL), in 384— well plates. Cell viability was measured after 6 hours incubation at 37°C, 5% 002 by adding 15 pL of ATP lite (Perkin Elmer) per well and reading on a ViewLux TS microplate imager (Perkin Elmer). Data was reported as CC50.

Measurement of eron production in human PBMC HUH7_EC50) Activation of human TLR7 results in robust tion of interferon by plasmacytoid dendritic cells present in human blood. The potential of compounds to induce interferon was evaluated by looking at the antiviral activity in the HCV replicon system upon tion with conditioned media from peripheral blood mononuclear cells . The HCV replicon assay is based on a bicistronic expression construct, as described by Lohmann et al. (Science (1999) 285: 110-113; Journal of Virology (2003) 77: 3007—15 3019) with modiﬁcations described by Krieger et al. (Journal of gy (2001) 75: 4614-4624). The assay utilized the stably transfected cell line Huh—7 luc/neo harboring an RNA encoding a ronic expression uct comprising the wild type NS3—NSSB regions of HCV type 1b ated from an internal Ribosome Entry Site (IRES) from encephalomyocarditis virus (EMCV), preceded by a er gene (Firefly-luciferase) and a selectable marker gene (neoR, neomycine phosphotransferase). The construct is ﬂanked by 5’ and 3’ NTRs (non—translated regions) from HCV type 1b. Continued culture of the replicon cells in the presence of G418 (neoR) is dependent on the replication of the HCV RNA. The stably transfected replicon cells that ate HCV RNA autonomously and to high levels, encoding inter alia luciferase, were used for profiling of the conditioned cell culture media. Briefly, PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll centrifugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 105 well were dispensed into 384—well plates containing compounds (70 pL total volume). After overnight incubation, pL of supernatant was transferred to 384-welt plates containing 2.2 x 103 replicon cellsfwell in 30 uL (plated the day before). Following 24 hours of incubation, replication -58— was measured by assaying luciferase activity using 40 pL/well Steady Lite Plus substrate (Perkin Elmer) and measured with ViewLux ultraHTS microplate imager (Perkin Elmer). The inhibitory activity of each compound on the uc/neo cells were reported as EC50 values, defined as the compound concentration applied to the PBMCs resulting in a 50% reduction of luciferase activity which in turn indicates the degree of replication of the replicon RNA on transfer of a defined amount of PBMC culture medium. Recombinant eron o-2a (Roferon-A) was used as a standard control compound. All compounds showed 0050 of >24uM in the HEK 293 TOX assay described above.

Measurement of interferon production in human PBMC (PBMC HEK-ISRE-luc LEC) Activation of human TLR7 s in robust production of interferon by cytoid dendritic cells t in human blood. The potential of compounds to induce eron was evaluated by determination of interferon in the conditioned media from peripheral blood mononuclear cells (PBMC). The presence of interferon in the samples was determined, using an interferon reporter cell line stably expressing an interferon-stimulated responsive elements (lSRE)—luc reporter uct. The lSRE element with sequence GAAACTGAAACT is highly responsive to the STAT1-STAT2- lRF9 transcription factor, which becomes activated upon binding of lFN—l to the lFN receptor. Briefly, PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll centrifugation ol. isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 105 cells/well were dispensed into 384-well plates containing compounds (70 uL total ). After overnight tion of the PBMCs with the compounds, 10 uL of supernatant was transferred to 384—well plates containing 5 x 103 RE—luc cells/well in 30 uL (plated the day ). Following 24 hours of incubation, activation of the lSRE elements was measured by assaying luciferase activity using 40 uL/well Steady Lite Plus substrate (Perkin Elmer) and measured with ViewLux ultraHTS microplate imager (Perkin Elmer). The stimulating activity of each compound on the HEK-lSRE-luc cells was reported as LEC. The LEC in turn indicates the degree of lSRE activation on transfer of a defined amount of PBMC culture medium. Recombinant interferon alfa-2a (Roferon-A) was used as a standard l compound.

The LEC values for the compounds in table 2 on HEK293 TLR8-NFDB-iuc and HEK293 NFZlB-Iuc where greater than the t tested concentration (> 10 pM for compound 6 and > 25 pM for all other compounds).

Table 2. Biological activity of compounds of formula (i) TLR7- TLR7- TLR7- TLR7- PBMC- PBMC STRUCTURE wt_LEC dIRR2__LEC wt__LEC leR2_LEC HUH7_EC50 HEK-lSRE-luc 24h (uM) 24h(p.M) 48h (th 48h(uM) (1.1M) (LEC;uM) H3N\ : “$9kam“ 2° 3 0.33 8.25 0.18 0.081 0.064 V<\:NH up; n 4147'“ “L43; 4.72 1.2 0.531 HN : ”/3 3 ﬂ *l W/ >2459- 767- 1397- O/<§/NH HEN n 7//O N/ \ N 0.077 1.23 0.04 0.16 0.12 <\/NH H2N H \ N N” / i“ \/_N\ [Na/k” @ 2.2 21.47 1.13 0.2 0.13 V\\j/NH “4 4 kw://“‘~/ 50 N,_(\N @ 0.66 6.32 0.34 0.053 0.04 wo 2013/068438 # TLR7- TLR7- TLR7- TLR7- PBMC— PBMC STRUCTURE wt_LEC dIRRZ_LEC wt_LEC leRZ_LEC HUH7_EC50 HEK-ISRE~Iuc 24h (uM) 24h (1.1M) 48h (1.1M) 48h (11M) (1.1M) __ 1-- _ __ ___ 77777 (LESS; 11M) -.~ H 871/ 7‘0 N 5.91 0.17 0.17 0.25 8 >11N ALSNH _____l—__._____ 9% 75°n 9 x1“ ~\.C>_ 0.88 0.07 0.05 0.03 H2N\ a ‘O, 19.0 94:?“ \1 13.93 >25 10.13 0.73 0.44 \\ NH “23%“? .36 0.19 0.33 0.32 >24.59 10.57 >25 9.75 16.94 01$“!EN HZN n “9 3:0 g\ N >24.59 3.23 20.31 3.81 2.58 wo 2013/068438 2012/072090 ~61- # TLR7- TLR7- TLR7- TLR7- PBMC- PBMC STRUCTURE wt_LEC leR2_LEC wt_LEC leR2_LEC HUH7_EC50 HEK-ISRE-Iuc 24h (11M) 24h (11M) 48h (1.1M) 48h (pM) (pm) -. _»»»»»» (LECHJM) 19 ”if/OH >24.59 13.31 >25 16.6 12.36 / \ H2 H /\ \F0 0.5 6.34 0.5 0.68 1. N@ H2' a N’ \ 1 0.23 0.007 0.13 0.12 23 H m LO 1.81 0.11 0.046 0.03 \ NH HZN H N,)\(:j/° “U (1.22“ N 2.46 0.39 0.006 0.007 x/‘NH HgN\ : “ix/1T0 0.2 1 0 005 26 01;):H \__Q— 2.42 . 0 0. 06 HZN H N’ \ T EN @ 6.03 0.63 0.8 0.43 wo 2013/068438 —62— # TLR7- TLR7— TLR7- TLR7- PBMC— PBMC STRUCTURE wt_LEC dIRR2_LEC wt_LEC leR2_LEC HUH7_EC50 HEK-ISRE-Iuc 24h(pM) 24h (pM) 48h (pM) 48h (1.1M) (11M) M) _ _____ 121;?"K /N-‘~./LNs \ >25 8.77 >23.81 >23.81 %/\§/NH H201 n 29 Nﬂw 1.58 1.66 0.82 >/4§NH HZN n N/ \ Yo N:2\” \’© 12.71 0.14 0.17 0.12 («\xNH r-2N H N- 4‘»? Q?)N 23.23 0.51 1.3 2.2 31 FWNH HZN H N/ \ 7;o 6.5 0.97 1.51 0.97 32 #2: N@N N\\:o HQN n N/ \ :F 0%: ”Q 2166 0.98 0.81 0.52 I \ HEN H P43N 0 N Nu...

NIT: >25 1.21 0.69 0.49 _i__ HzN H N/Fva-0\\ / 0.36 0.033 0.17 0.10 w)»: G/N /—N\ wo 20131068438 # TLR7- TLR7- TLR7- TLR7- PBMC- PBMC STRUCTURE wt_LEC leRZ_LEC wt_LEc leR2_LEC HUH7_EC50 HEK-ISRE-Iuc Z4h(|1M) 24h(uM) 48h ) 48h(uM) (HM) _,,,,,, ___,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, . ﬂ 7(I-EC; 11M) __ ”21260n N)=N \'© o 22 0 047 0 033 36 ' o 017' ’ ‘ HZN a 31‘ T‘N 37 C‘N 0.05 0,01 H7N H 31‘ N 0.38 >25 HZN H N \ 7‘0 40 @‘N \‘QO 2?: 0 03' o 01' HQN n N \ To 3:“ Q0 0.03 0.40 41 C 97% wo 2013/068438 ~64— # TLR7- TLR7- TLR7- TLR7- PBMC- PBMC URE wt_LEC dIRR2_LEC wt_LEC leR2_LEC HUH7_EC50 HEK-ISRE-Iuc 24h (1.1M) 24h(p.M) 48h (1.1M) 48h(uM) (pM) (LEC;|.1M) A __‘__ ___ HzN R 43 KN \—{\/N / 0.50 0.15 HZN n M’ \ f0 H ‘N 0.10 0.04 44 U)‘ / N\ \‘qo HZN n H ‘N 0.58 1.37 N\,Nj‘ Q OF H2N a g \N 0.21 0.03 46 \ Q N\ 0H HzN R N: \ T “122‘N \’O 14.12 47 k 1.64 IP\=O /\0 o HQN E N/\ T N‘ \ \ N / 0.01 001 48 N)=N H2N H V T\ / \ N 0.31 0.06 49 C ‘Q # TLR7- TLR7- TLR7- TLR7- PBMC- PBMC STRUCTURE wt_LEC LEC wt_LEC leR2_LEC HUH7_EC50 HEK-ISRE-Iuc 24h (pM) 24h (1.1M) 48h (pM)___ 48h (1.1M) (pM) (LEC;|.lM)___—__ ______________ _ ﬂ _ ’ HqN H N:\ N / N\ N 0.03 0.01 ° C‘ ’ WYn /ON n ‘N P<3 51 NI\\ 0-16 0.17 51”?” }“— :urN' ’Ir‘oﬁ N \ - *" 16-1 5.65 0.05 0.07 54 g HQN H N’ \ f N:e\~N 55 4.11 0.06 1.27 1.16 <\/NH ;=o H2N 1 \ >\_/ \19 0 I \\ I 0A0 N N:N/_N\v_(\<:\_, O44- 0.06 1.21 1.38 57 Q.“_ “N wo 2013/068438 TLR7— TLR7- TLR7- TLR7- PBMC— PBMC STRUCTURE wt_LEC leR2_LEC wt_LEC leR2_LEC HUH7_EC50 HEK-ISRE-luc ”ElihﬂAM) 24h (pM) 48h (pM) 48h (11M) (pM) (LECHJM) HQN H ),\ N\/_o OH “' \ F , l—< ~18“ pr,\ 2—~\ ° 0.99 0.06 2.75 2.69 HgN‘ : Niﬁw// 7/0 ” "4% ~:( >25 1.25 0.034 0.019 60 V/AV/NH u HZN‘ a (Ly? >194 \__, N... 61 RN“ RN,» >25 9.73 1.34 0.95 ‘ t———.— V\‘/{m R 21.2 >25 0.70 0.72 HZN RI N/ \ 2F \ O 63 hem \’<:> >25 2.58 6.72 4.39 g/N” All the compounds were tested in the reporter assays for ment of TLR8 activity and showed LEC >17 0M.

Claims

1. A compound of formula (I) A /¥o R1 N/ N\ Y_‘R2 (I), or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein Y is (01-4) alkylene, R1 is selected from the group comprising an imidazolyl, a lyl or a pyridinyl each of which is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, 01-6 alkyl, koxy or C3_6 cycloalkyl and R2 is an aryl2 or a heterocyciyl with the o that the compound of formula (l) is not 9-benzylhydroxy-2—(3— 10 pyridyl)—adenine or its tautomers. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 er with one or more ceutically acceptable excipients, diluents or carriers. 15 A compound of formula (l) or a pharmaceutically acceptable salt, e or polymorph f according to claim 1, or a pharmaceutical composition ing to claim 2 for use as a medicament. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1, or a pharmaceutical composition 20 according to claim 2, for use in the treatment of a disorder in which the modulation of TLR7 is involved. Use of a compound according to any one of claims 1 to 4, in the production of a medicament for treating a disorder in which the modulation of TLR7 is involved. A compound according to a (l) substantially as herein described with 25 reference to any one of the accompanying examples thereof.